Generation of atrial and ventricular cell lineages from human pluripotent stem cells

By differentiating pluripotent stem cells with BMP, activin, and retinoic acid, the method achieves enriched atrial and ventricular cardiomyocyte populations, addressing the limitations of mixed stem cell therapies and enhancing cardiac repair efficacy.

JP2024163197AInactive Publication Date: 2024-11-21UNIV HEALTH NETWORK
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024150822
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-12-06
Filing Date
2024-09-02
Publication Date
2024-11-21
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current therapies for heart disease focus on slowing the progression of heart failure rather than restoring lost systolic function, and stem cell-based treatments face challenges such as mixed cardiomyocyte populations that can lead to issues like graft-associated ventricular tachyarrhythmias, necessitating the development of enriched populations of specific cardiomyocyte subtypes like atrial and ventricular cardiomyocytes for therapeutic applications.

Method used

A method involving the use of BMP components, activin components, and retinoic acid to differentiate pluripotent stem cells into enriched populations of atrial and ventricular cardiomyocytes, characterized by specific markers like RALDH2, CD235, and CYP26A1, with optimized concentrations to minimize pacemaker cells.

Benefits of technology

The method produces cardiomyocyte populations that are at least 50-99% enriched in atrial or ventricular cells, essentially free of pacemaker cells, suitable for cardiac repair and therapeutic applications, reducing the risk of arrhythmias and improving cardiac function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163197000001_ABST
    Figure 2024163197000001_ABST
Patent Text Reader

Abstract

To provide generation of atrial and ventricular cell lineages from human pluripotent stem cells.SOLUTION: Disclosed is a method for preparing a population of myocardial cells from a pluripotent stem cell. The population may be enriched for either atrial or ventricular myocardial cells, and the resulting ventricular population may be essentially free from pacemaker cells. The method comprises incubating pluripotent cells in a suitable medium containing BMP component and activin component, where the amount of activin may be varied to enrich either atrial or ventricular cardiomyocytes. The enriched populations, as well as a method for treating a patient in need of cardiac repair using the same are disclosed.SELECTED DRAWING: Figure 15
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 U.S.C. § 119 to U.S. Provisional Application Serial No. 62 / 429,823, filed December 4, 2016, and U.S. Provisional Application Serial No. 62 / 430,815, filed December 6, 2016. The entire contents of these prior patent applications, including but not limited to the specification, claims, and abstract, as well as any drawings, tables, or figures thereof, are expressly incorporated herein by reference.

[0002] The present disclosure provides methods for producing and compositions comprising enriched populations of atrial and ventricular cardiomyocytes, as well as uses thereof for therapeutic treatments, disease modeling, and drug discovery, as well as biomarkers and methods for identifying these enriched subpopulations. [Background technology]

[0003] The goal of heart disease research is to understand in more detail what and why happens in heart disease, and to discover ways to prevent damage or repair or replace damaged heart tissue. Existing therapies aim to slow the progression of heart failure rather than restore lost contractile function. Currently, the only available therapeutic option to replace lost contractile function is whole organ transplantation, but as demand greatly exceeds supply, there has been great interest in stem cell-based therapies as an alternative approach. The availability of cardiomyocytes differentiated from stem cells for transplantation purposes would be particularly useful. Various studies have demonstrated that the use of human embryonic stem cell (hESC)-derived cardiomyocytes can re-hypertrophy damaged heart muscle and mediate improved contractile function when transplanted (see, for example, Shiba et al., 2012). However, one of the challenges is the mixed nature of stem cell-derived cardiomyocyte populations, which can contribute to problems such as graft-associated ventricular tachyarrhythmias. What is needed is the ability to further differentiate stem cells to allow the formation of specific enriched populations of cardiomyocyte subtypes, such as ventricular and atrial cardiomyocytes, and to be able to use these enriched populations of cardiomyocytes for therapeutic purposes. Summary of the Invention [Means for solving the problem]

[0004] In one aspect, a method of producing a population of cardiomyocytes enriched in atrial cardiomyocytes is provided, the method comprising the steps of: i. incubating pluripotent stem cells to generate atrial mesoderm in a mesoderm induction medium comprising at least a BMP component, optionally BMP4, and an effective amount of an activin component, optionally activin A. In this aspect, the method comprises further adding a retinoic acid component to the cells during the mesoderm induction or cardiovascular lineage commitment stage, and culturing the cells such that a population of cardiomyocytes enriched in atrial cardiomyocytes is generated.

[0005] In one aspect, the atrial mesoderm may be characterized by the cells being one or more of RALDH2 positive, CD235 negative, and CYP26A1 negative. In one embodiment, the BMP component is provided in a ratio of 3:2 to the Activin component. In another embodiment, the Activin component is present in an amount of about 0.001ng / ml to 6ng / ml, and the BMP component is present in an amount of about 3ng / ml to about 100ng / ml.

[0006] In one aspect, a method for producing a population of cardiomyocytes enriched for ventricular cardiomyocytes is provided, the method comprising incubating pluripotent stem cells in a mesoderm induction medium containing a BMP component, optionally BMP4, sufficient to generate ventricular mesoderm, and an effective amount of an activin component, optionally activin A, and then culturing the cells in a suitable medium to generate a population of cardiomyocytes enriched for ventricular cardiomyocytes. In one embodiment, the amount of activin component effective to generate ventricular mesoderm is characterized by one or more of RALDH2 negative, CD235a positive, and CYP26A1 positive. In another embodiment, the concentration of the activin component is higher than the concentration of the BMP component. In one embodiment, the activin component is present in an amount of about 6 ng / ml to 20 ng / ml, and the BMP is present in an amount of about 3 ng / ml to about 20 ng / ml.

[0007] In one embodiment, a population of cardiomyocytes enriched in ventricular cardiomyocytes is provided, which is essentially free of pacemaker cells. In another embodiment, the population is devoid of pacemaker cells. In another embodiment, an isolated population of cardiomyocytes enriched in ventricular cardiomyocytes is provided, which comprises at least or about 50% ventricular cardiomyocytes, at least or about 60% ventricular cardiomyocytes, at least or about 70% ventricular cardiomyocytes, at least or about 80% ventricular cardiomyocytes, at least or about 90% ventricular cardiomyocytes, at least about 95% ventricular cardiomyocytes, or at least about 99% ventricular cardiomyocytes, preferably obtained according to the method described herein. In one embodiment of the present invention, the isolated population is essentially free of pacemaker cells (less than 5% of total cells). In preferred embodiments, the population contains less than 1% pacemaker cells, less than 0.5% pacemaker cells, less than 0.1% pacemaker cells, less than 0.01% pacemaker cells, less than 0.001% pacemaker cells, 0.0001% pacemaker cells, or is completely devoid of pacemaker cells. Without wishing to be bound by any theory, it is envisioned that the presence of pacemaker cells may induce independent and separate contractions of muscles when introduced into a patient. In preferred embodiments, pacemaker cells are not detectable in the isolated population of ventricular cardiomyocytes using currently available techniques.

[0008] In one aspect, there is provided an isolated population of cardiomyocytes enriched in atrial cardiomyocytes, comprising at least or about 50% atrial cardiomyocytes, at least or about 60% atrial cardiomyocytes, at least or about 70% atrial cardiomyocytes, at least or about 80% atrial cardiomyocytes, or at least or about 90% atrial cardiomyocytes, or at least or about 95% atrial cardiomyocytes, or at least or about 99 atrial cardiomyocytes, preferably obtained according to a method described herein.

[0009] In one aspect, a method is provided for treating a subject in need of cardiac repair, such as a subject having or at risk for heart failure, comprising administering to the subject a population of ventricular cardiomyocytes described herein.

[0010] In one aspect, there is provided a population of ventricular cardiomyocytes as described herein for use in treating a subject in need of cardiac repair, such as a subject having or at risk for heart failure.

[0011] In one aspect, there is provided a use of a population of ventricular cardiomyocytes described herein in the preparation of a medicament for the treatment of a subject in need of cardiac repair, such as a subject having or at risk of heart failure.

[0012] In one aspect, a method for detecting atrial mesoderm in a population of cells is provided, comprising detecting ALDH, preferably RALDH2, wherein the presence of ALDH, preferably RALDH2, is indicative of atrial mesoderm.

[0013] In one aspect, a method is provided for detecting ventricular mesoderm in a population of cells, the method comprising detecting one or more of CD235a, CD235b, and CYP26A1, wherein the presence of CD235a, CD235b, and / or CYP26A1 is indicative of ventricular mesoderm.

[0014] Other features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and specific examples, while indicating preferred embodiments of the present disclosure, are given by way of illustration only, and various changes and modifications within the spirit and scope of the present disclosure will become apparent to those skilled in the art from this detailed description. In certain embodiments, for example, the following are provided: (Item 1) A population of cardiomyocytes enriched for ventricular cardiomyocytes, the population being essentially free of pacemaker cells. (Item 2) 2. The population of item 1, which is devoid of pacemaker cells. (Item 3) 3. A pharmaceutical composition for treating heart failure or myocardial infarction in a patient, comprising a population of cardiomyocytes according to item 1 or 2 and a pharma- ceutical acceptable carrier. (Item 4) 1. A method for producing a population of cardiomyocytes enriched for ventricular cardiomyocytes, comprising: incubating pluripotent stem cells in a mesoderm induction medium, the mesoderm induction medium comprising a BMP component sufficient to generate ventricular mesoderm and an effective amount of an activin component, and thereafter Culturing the incubated cells in a suitable medium to generate a population of cardiomyocytes enriched for ventricular cardiomyocytes. A method comprising: (Item 5) 5. The method of claim 4, wherein the concentration of the activin component is greater than the concentration of the BMP component. (Item 6) 6. The method of claim 4 or 5, wherein the ratio of the BMP component to the activin component is about 0.3-1:1, about 0.5:1, or about 0.8:1. (Item 7) 7. The method according to any one of items 4 to 6, wherein the concentration of the activin component is determined by measuring the level of mesodermal cells expressing CD235a and comparing this to the level of mesodermal cells expressing RALDH2. (Item 8) 8. The method of any one of items 4 to 7, wherein the concentration of the activin component is selected by determining a concentration that preferentially results in more mesodermal cells expressing CD235a compared to mesodermal cells expressing RALDH2. (Item 9) 9. The method according to any one of items 4 to 8, wherein the activin component is added in an amount of about 4 ng / ml to about 20 ng / ml. (Item 10) 10. The method according to any one of items 4 to 9, wherein the concentration of the activin component is 6 to 20 ng / ml. (Item 11) 11. The method according to any one of items 4 to 10, wherein the concentration of the BMP component is from about 3 ng / ml to about 20 ng / ml. (Item 12) 12. The method according to any one of items 4 to 11, wherein the concentration of the BMP component is 5 ng / ml or 10 ng / ml. (Item 13) 13. The method according to any one of items 4 to 12, wherein the concentration of the activin component is 12 ng / ml. (Item 14) 14. The method according to any one of items 4 to 13, wherein the BMP component is BMP4. (Item 15) 15. The method according to any one of items 4 to 14, wherein the activin component is activin A. (Item 16) 16. The method according to any one of items 4 to 15, wherein at least a portion of the population of generated cardiomyocytes is used to treat a subject in need of cardiac repair. (Item 17) 17. The method of claim 16, wherein the subject in need of cardiac repair is at risk of heart failure, suffers from heart failure and / or has suffered from the onset of myocardial infarction. (Item 18) 18. The method according to item 17, wherein the treatment is administered before, during or after the onset of a myocardial infarction. (Item 19) 1. A method for producing a population of cardiomyocytes enriched for atrial cardiomyocytes, comprising: incubating pluripotent stem cells in a mesoderm induction medium, the mesoderm induction medium comprising a sufficient BMP component and an effective amount of an activin component to generate atrial mesoderm, and thereafter adding a retinoic acid component to the cells, said adding occurring during or after said incubation in mesoderm induction medium; and Culturing the incubated cells to produce a population of cardiomyocytes enriched for atrial cardiomyocytes. A method comprising: (Item 20) 20. The method of claim 19, wherein the retinoic acid component is added when the cells are RALDH2 positive and CD235a negative. (Item 21) 21. The method of claim 19 or 20, wherein the ratio of the BMP component to the activin component is about 1.5 to 1 or higher. (Item 22) 22. The method of any one of items 19 to 21, wherein the ratio of the BMP component to the activin component is 3:2. (Item 23) 23. The method according to any one of items 19 to 22, wherein the BMP component is present at a concentration of about 3 ng / ml to about 100 ng / ml. (Item 24) 24. The method of any one of items 19 to 23, wherein the BMP component is present in an amount of about 3 ng / ml. (Item 25) 25. The method of any one of items 19 to 24, wherein the activin component is present in an amount of about 0.01 ng / ml to about 6 ng / ml. (Item 26) 26. The method of any one of items 19 to 25, wherein the activin component is present in an amount of about 2 ng / ml. (Item 27) 27. The method according to any one of items 19 to 26, wherein the retinoic acid component is trans-retinoic acid or retinol. (Item 28) 28. The method according to any one of items 19 to 27, wherein the retinoic acid component is added at a concentration of 50 nm to 5 μM. (Item 29) 29. The method according to any one of items 19 to 28, wherein the retinoic acid component is added at a concentration of 500 nM. (Item 30) 30. The method according to any one of items 19 to 29, wherein the BMP component is BMP4. (Item 31) 31. The method according to any one of items 19 to 30, wherein the activin component is activin A. (Item 32) 32. The method according to any one of items 19 to 31, wherein the BMP component is added to the mesoderm induction medium after 1 day. (Item 33) 32. The method according to any one of items 19 to 31, wherein the activin component is added to the mesoderm induction medium after one day. (Item 34) 34. The method of any one of items 19 to 33, wherein the retinoic acid component is added on about day 3 to 5 of the method. (Item 35) 35. The method of any one of items 19 to 34, wherein no additional BMP components are added to the mesoderm induction medium on day 3 of the method. (Item 36) 36. The method of any one of items 19 to 35, wherein no FGF inhibitor is provided to the mesoderm induction medium on day 3 of the method. (Item 37) 37. The method according to any one of items 4 to 36, further comprising incubating the pluripotent stem cells in a medium suitable for aggregation and / or embryoid body formation prior to incubating the pluripotent stem cells in the mesoderm induction medium. (Item 38) 38. The method according to any one of items 4 to 37, wherein the cells produced by said method are utilized in an in vitro assay for screening potential therapeutic compounds. (Item 39) An isolated population of cardiomyocytes enriched in atrial cardiomyocytes, the population comprising at least or about 50% atrial cardiomyocytes, at least or about 60% atrial cardiomyocytes, at least or about 70% atrial cardiomyocytes, at least or about 80% atrial cardiomyocytes, or at least or about 90% atrial cardiomyocytes. (Item 40) 40. A population of cardiomyocytes according to item 39, obtained according to the method according to any one of items 18 to 38. (Item 41) An isolated population of cardiomyocytes enriched in ventricular cardiomyocytes, the population comprising at least or about 50% ventricular cardiomyocytes, at least or about 60% ventricular cardiomyocytes, at least or about 70% ventricular cardiomyocytes, at least or about 80% ventricular cardiomyocytes, or at least or about 90% ventricular cardiomyocytes. (Item 42) 42. The population of item 41, essentially free of or devoid of pacemaker cells. (Item 43) 43. The population according to item 41 or 42, obtained according to the method according to any one of items 4 to 17. (Item 44) 44. A method of treating a subject in need of cardiac repair, comprising administering to said subject a population of cardiomyocytes according to any one of items 1, 2, or 41-43. (Item 45) 45. The method of claim 44, wherein the subject is at risk of heart failure, suffers from heart failure and / or has experienced the onset of a myocardial infarction. (Item 46) 46. ​​The method of claim 45, wherein the myocardial infarction is in the patient's ventricle. (Item 47) 43. The population of cardiomyocytes of any one of items 1, 2, or 40-42 for use in treating a subject in need of cardiac repair. (Item 48) 44. Use of a population of cardiomyocytes according to any one of items 1, 2 or 41 to 43 in the preparation of a medicament for treating a subject in need of cardiac repair. (Item 49) A method for detecting atrial mesoderm in a population of mesodermal cells, comprising detecting RALDH2, the presence of RALDH2 being indicative of atrial mesoderm. (Item 50) 20. A method for detecting ventricular mesoderm in a population of mesodermal cells, comprising detecting CD235a, the presence of CD235a being indicative of ventricular mesoderm. (Item 51) 1. A method for producing a population of cardiomyocytes enriched for sinoatrial node pacemaker cells or epicardial cells, comprising: incubating the pluripotent stem cells in a mesoderm induction medium, the mesoderm induction medium further comprising a BMP component and an activin component in an amount sufficient to generate ALDH+ / CD235- mesoderm, and thereafter Culturing the incubated cells in a suitable medium containing one or more of WNT, FGF1 and BMP to generate a population of cardiomyocytes enriched for sinoatrial node pacemaker cells or epicardial cells. A method comprising: (Item 52) 52. A population of cardiomyocytes produced by the method according to item 51. (Item 53) A method for screening or evaluating the potential cardiotoxicity of a test compound or agent, comprising exposing a population of cardiomyocytes described in any of the preceding cell population items to the test compound and evaluating viability, contractility, changes in electrical potential and / or other functions of the cells. [Brief description of the drawings]

[0015] Embodiments of the present disclosure will now be described in connection with the drawings.

[0016] [Figure 1]RA signaling promotes the development of atrial-like cardiomyocytes. (A) Blueprint of hPSC cardiomyocyte differentiation protocol indicating developmental stages and timing of RA addition. (B and C) qRT-PCR analysis of expression levels of (B) total cardiomyocyte genes and (C) ventricular-specific (MYL2) and atrial-specific (KCNJ3) genes in NKX2-5+SIRPa+CD90- cells (n=3) and fetal tissue controls (n=6) isolated from day 20 EB populations induced with 10 ng / mL BMP4 and 6 ng / mL activin A (10B / 6A) and treated with RA at the indicated time points (t-test, *p<0.05 and **p<0.01 vs. DMSO control and ##p<0.01 vs. FV vs. FA). (D) Heatmap comparing gene expression profiles of NKX2-5+SIRPa+CD90- cells isolated from day 20 EBs (induced with 10B / 6A) treated with RA or DMSO (control) on days 3-5 (n=5). Values ​​represent the log10 of expression levels relative to the housekeeping gene TBP. (E) Representative flow cytometry analysis of the percentage of NKX2-5+ / CTNT+ and MLC2V+ / CTNT+ cells in day 20 EB populations induced with 10B / 6A and treated with RA or DMSO (control) on days 3-5. (F) Bar graph showing the mean percentage of MLC2V+CTNT+ cells in day 20 EBs treated as indicated (t-test, **p<0.01 vs. DMSO control; n=4). (G and H) Photomicrographs showing immunostaining for (G)MLC2V and (H)COUPTFII in day 20 EBs (induced with 10B / 6A) treated with either DMSO (control) or RA on days 3–5. Cells were co-stained with CTNT to identify all cardiomyocytes and DAPI to visualize all cells. Scale bars represent 100 mm. For all PCR analyses, values ​​of expression were normalized to the housekeeping gene TBP. Error bars represent SEM. FV, fetal ventricular tissue; FA, fetal atrial tissue. See also Figure 8.

[0017] [Diagram 2]Induction of ALDH+ cardiac mesoderm. (A) Representative flow cytometric analysis of ALDH activity in PDGFRalpha+ mesoderm in 10B / 6A-induced EBs. Cells treated with ALDH inhibitor (DEAB) were used as control. (B and C) Representative flow cytometric analysis of ALDH activity and PDGRalpha expression (left column) at day 4 and corresponding expression of CTNT at day 20 after manipulation (days 1-3) of (B) Activin A concentration (0.110 ng / mL) in the presence of 10 ng / mL BMP4 or (C) BMP4 concentrations (1-10 ng / mL) in the presence of 2 ng / mL Activin A. (D) Representative flow cytometric analysis of ALDH activity and PDGFRalpha expression in 3B / 2A-induced EBs. (E) qRT-PCR analysis of ALDH1A2 and CYP26A1 expression levels in 10B / 6A and 3B / 2A induced EB populations (t test, *p<0.05 and **p<0.01 vs. 10B / 6A induced EBs at the corresponding differentiation days; n=4). For all PCR analyses, expression values ​​were normalized to the housekeeping gene TBP. Error bars represent SEM. See also Figure 9.

[0018] [Diagram 3]Retinol commits AF+ mesoderm to an atrial fate. (A) Schematic of the strategy used to isolate and analyze cardiac differentiation potential of ALDH+PDGFRa+ (fraction I) and ALDH-PDGFRa+ (fraction II) fractions isolated from 3B / 2A-induced day 4 EBs. (B) Representative flow cytometry plots showing the cell sorting strategy used to isolate ALDH+PDGFRa+ (fraction I) and ALDH-PDGFRa+ (fraction II) fractions. (C) qRT-PCR analysis of expression of ALDH1A2 within the isolated populations indicated above (t test, **p<0.01; n=3). (D and E) Flow cytometry analysis of the percentage of (D) CTNT+ and (E) MLC2V+ cells in day 20 populations generated from day 4 ALDH+PDGFRa+ and ALDH-PDGFRa+ fractions treated with ROH-, RA-, or DMSO (control) (t-test, *p<0.05 and **p<0.01 vs. DMSO control; n=6). (F and G) qRT-PCR analysis of expression levels of (F) ventricular and (G) atrial genes in day 20 populations of the indicated treatment groups (n=6) (t-test, *p<0.05 and **p<0.01 vs. DMSO control). For all PCR analyses, expression values ​​were normalized to the housekeeping gene TBP. Error bars represent SEM. WNTi, WNT inhibitor; ROH, retinol. See also Figure 10.

[0019] [Figure 4]CD235a expression marks mesoderm with ventricular differentiation potential. (A) Representative flow cytometry analysis of CD235a expression and ALDH activity in either 10B / 6A (top) or 3B / 2A (bottom) induced EBs. (B) Representative flow cytometry plots showing the cell sorting strategy used to isolate CD235a+ (fraction III, ventricular differentiation potential) and ALDH+ (fraction IV, atrial differentiation potential) fractions from day 4 5B / 4A induced EBs. (C and D) Flow cytometry analysis of the percentage of (C) CTNT+ and (D) MLC2V+ cells in day 20 populations generated from day 4 ALDH+ and CD235a+ fractions treated with ROH, RA, or DMSO (control) for 24 hours (t test, *p<0.05 and **p<0.01 vs. DMSO control and ##p<0.01 vs. indicated samples; n=5). (E and F) qRT-PCR analysis of (E) ventricular and (F) atrial gene expression levels in day 20 populations generated from day 4 ALDH+ and CD235a+ fractions treated as indicated (n=5) (t test, *p<0.05 and **p<0.01 vs. DMSO control, #p<0.05 and ##p<0.01 vs. indicated samples). For all PCR analyses, expression values ​​were normalized to the housekeeping gene TBP. Error bars represent SEM, see also Figure 11.

[0020] [Figure 5A-G]Optimization of CD235a+ cardiac mesoderm induction. (A and B) Representative flow cytometry analysis of ALDH activity and CD235a expression at day 4 (left column) and corresponding MLC2V and CTNT expression at day 20 (right column) following manipulation (days 1-3) of (A) Activin A concentrations (2-20 ng / mL) in the presence of 10 ng / mL BMP4 or (B) BMP4 concentrations (3-20 ng / mL) in the presence of 12 ng / mL Activin A. (C) Representative flow cytometry plots showing the percentage of ALDH activity and CD235a expression in day 4 5B / 12A (top) and 3B / 2A-induced EBs (bottom). (D and E) Flow cytometric analysis of the percentage of (D) CTNT+ cells and (E) MLC2V+ cells in day 20 EB populations from 5B / 12A- or 3B / 2A-induced EBs treated with ROH, RA, or DMSO (control) for 48 hours (days 3-5) (t-test, *p<0.05 and **p<0.01 vs. DMSO control; n=4). (F and G) qRT-PCR analysis of expression levels of (F) ventricular and (G) atrial genes in day 20 EB populations generated with the indicated treatments (n=4) (t-test, *p<0.05 and **p<0.01 vs. DMSO control). (H) Flow cytometric analysis of representative percentages of the percentage of NKX2-5-CTNT+ cells in day 20 EB populations induced with 5B / 12A or 3B / 2A. (I) Quantification of the autonomous beating rate of day 20 EBs induced with 5B / 12A or 3B / 2A (n=17) (t-test, **p<0.01). (J) Bar graph showing the mean percentage of NKX2-5-CTNT+ cells in day 20 EB populations induced with 5B / 12A, 10B / 6A, or 3B / 2A (days 1-3) in the presence or absence of RA (0.5 mM, days 3-5) (t-test, *p<0.05 for the indicated samples; n=5). For all PCR analyses, expression values ​​were normalized to the housekeeping gene TBP. Error bars represent SEM. See also Figure 12. [Figure 5H-J] Same as above

[0021] [Figure 6]Comparison of cardiomyocytes derived from different mesodermal populations. (A and B) qRT-PCR analysis of expression levels of (A) total cardiomyocyte and (B) ventricular genes in NKX2-5+SIRPa+CD90- cells (n=5) and fetal tissue controls (n=6) isolated from day 20 EBs induced under ventricular induction (VI), mixed induction (also called Ml, MM), and atrial induction (AI) conditions (t-test, *p<0.05 and **p<0.01 for the indicated samples, ##p<0.01, FV vs. FA). (C) qRT-PCR analysis (n=4) of expression levels of atrial genes in NKX2-5+SIRPa+CD90- cells isolated from day 20 untreated or RA-treated EBs (days 3-5) induced as indicated (t-test, *p<0.05 and **p<0.01, VI vs. VI+RA. (D) Photomicrographs showing immunostaining of COUPTFII in NKX2-5+SIRPa+CD90- cells isolated from day 20 EBs induced with VI+RA or AI+RA. Cells were co-stained with CTNT to identify all cardiomyocytes and DAPI to visualize all cells. Scale bar represents 100 mm. (E-G) AP measurements in NKX2-5+SIRPa+CD90- cardiomyocytes isolated from day 20 EBs induced as indicated. (E) Representative recordings of autonomous APs in individual cardiomyocytes isolated from the indicated groups. (F) Quantification of AP duration at 30% / 90% repolarization (APD30 / 90) in cardiomyocytes isolated from VI (n=18), VI+RA (n=18), and AI+RA (n=20) EBs (t-test, *p<0.05 and **p<0.01 for the indicated samples). (G) Based on the analysis of recorded APs, the AP durations at 30% / 90% repolarization (APD30 / 90) in each group were significantly shorter than those at 30% / 90% repolarization (APD30 / 90) in each group. Bar graphs showing the percentage of mature (maximal rise velocity [dv / dtmax] < 10 and cycle length [CL]R 0.3) and immature (maximal rise velocity [dv / dtmax] < 10 and cycle length [CL]R 1). (H-J) Analysis of acetylcholine-activated inward rectifier potassium current density (IKACh) in cardiomyocytes isolated from EBs induced as indicated.(H) Representative recordings showing CCh-sensitive currents (IKACh) in cardiomyocytes isolated from AI+RA-induced EBs, quantified as the difference between the currents measured after (CCh) and before (control) application of 10 mM carbachol (CCh) (inset: voltage protocol). (I) Current-voltage relationship for IKACh current density in ventricular cardiomyocytes isolated from VI EBs (verified by ventricular-like AP morphology) and atrial cardiomyocytes isolated from VI+RA and AI+RA EBs (verified by atrial-like AP morphology). (J) Quantification of maximum IKACh current density recorded at -120 mV in each group (t-test, *p<0.05 and **p<0.01 for the indicated samples). For all PCR analyses, expression values ​​were normalized to the housekeeping gene TBP. Error bars represent SEM. FV, fetal ventricular tissue; FA, fetal atrial tissue; ns, not significant. See also Figure 13.

[0022] [Figure 7]Generation of ventricular and atrial cardiomyocytes from other hPSC lines. (A) Representative flow cytometry analysis of ALDH activity and CD235a expression in day 4 HES2-derived EBs induced under ventricular (5B / 6A, top) or atrial (5B / 2A, bottom) conditions. (B) Representative flow cytometry analysis of CTNT and MLC2V expression in the corresponding day 20 EB populations generated under ventricular or atrial conditions and subjected to ROH, RA, or DMSO (control) treatment on days 3–5. (C and D) qRT-PCR analysis of expression levels of (C) ventricular and (D) atrial genes in SIRPa+CD90- cells isolated from day 20 EBs induced under the indicated conditions (t-test, *p<0.05 vs. DMSO control, #p<0.05 and ##p<0.01 vs. indicated samples; n=5). (E) Representative flow cytometry analysis of ALDH activity and CD235a expression in day 4 MSC-iPS1-derived EBs induced under ventricular (4B / 4A, top) or atrial (4B / 1A+SB, bottom) conditions. (F) Representative flow cytometry analysis of CTNT and MLC2V expression in the corresponding day 20 EB populations generated in ventricular or atrial conditions and subjected to ROH, RA, or DMSO (control) treatment on days 3-5. (G and H) qRT-PCR analysis of expression levels of (G) ventricular and (H) atrial genes in SIRPa+CD90- cells isolated from day 20 EBs induced as indicated (t-test, *p<0.05 and **p<0.01 vs. DMSO control, ##p<0.01 vs. indicated samples; n=5). (I) Model of human atrial and ventricular cardiomyocyte generation from hPSCs. In this model, distinct mesodermal populations defined by expression of CD235a and CYP26A1 or expression of RALDH2 and ALDH activity are induced by different concentrations of activin A and BMP4. RALDH2+ALDH+ mesoderm can generate atrial-like cardiomyocytes in response to ROH, whereas CD235a+CYP26A1+ cannot. RA can commit both mesodermal populations to an atrial fate. However, lineage commitment from CD235a+ mesoderm is less efficient than that from RALDH2+ mesoderm, and the resulting atrial phenotype is suboptimal.In the absence of retinoid signaling (ROH, RA), RALDH2+ mesoderm can give rise to ventricular cardiomyocytes with low efficiency. For all PCR analyses, expression values ​​were normalized to the housekeeping gene TBP. Error bars represent SEM. SB, SB-431542 (Nodal / Activin A / TGF-b inhibitor); WNTi, WNT inhibitor. See also Figure 14.

[0023] [Figure 8] Referring to Figure 1. Generation of atrial-like cardiomyocytes from hPSCs. (A) Representative flow cytometry plots showing the cell sorting strategy used for the isolation of SIRP alpha+NKX2-5+CD90- cardiomyocytes on day 20 of differentiation. (B-E) Graphs of QRT-PCR analysis represented as heat maps in Figure 1D showing expression levels of (B) total cardiomyocytes, (C) ventricular cardiomyocytes, (D) atrial cardiomyocytes, (E) cardiac ion channel and connexin channel genes in SIRP alpha+NKX2-5+CD90- cardiomyocytes isolated from EBs induced with 10B / 6A and treated with either RA or DMSO (control) on days 3-5 of differentiation (n=5). t-test: *P<0.05, **P<0.01 vs. DMSO control, ##P<0.01 vs. FV vs. FA. (F) qRT-PCR analysis of expression levels of retinoic acid receptor isoforms (RARA, RARB, and RARG) in the total 10B / 6A-derived EB population at the indicated days of differentiation (n=3). (G) Flow cytometry analysis of the percentage of CTNT+ cells in day 20 EBs treated with either DMSO (control), RA, or receptor-specific agonists on days 3-5 (n=3). (H) qRT-PCR analysis of expression levels of the ventricular-specific gene MYL2 in day 20 EBs treated on days 3-5 with the indicated treatments (n=3). t-test: **P<0.01 versus DMSO control. For all PCR analyses, expression values ​​were normalized to the housekeeping gene TBP. Error bars represent SEM. FV: fetal ventricular tissue, FA: fetal atrial tissue, RA: retinoic acid, AM580: RAR alpha agonist, AC55649: RAR agonist, CD437: RAR gamma agonist.

[0024] [Figure 9] Related to Figure 2. Developmental kinetics of mesoderm induced with 10B / 6A and 3B / 2A. (A) Bar graph showing the average number of cells generated per well of a 6-well plate of EBs (day 20) induced with 3B / 2A and 10B / 6A (n=5). (B) QRT-PCR analysis of the expression kinetics of ALDH1A1 and ALDH1A3 aldehyde dehydrogenase isoforms in EBs at the indicated days of differentiation after induction (days 1-3) with either 3B / 2A or 10B / 6A (n=3). (C) QRT-PCR analysis of the expression kinetics of the primitive streak marker T (Brachyury) and the cardiac mesoderm marker MESP1 in EBs at the indicated days of differentiation after induction (days 1-3) with either 3B / 2A or 10B / 6A (n=4). For all PCR analyses, expression values ​​were normalized to the housekeeping gene TBP. Error bars represent SEM.

[0025] [Figure 10] ALDH activity in 3B / 2A-induced mesodermal populations. Representative flow cytometric analysis of ALDH activity after 24 h of culture as aggregates of ALDH+PDGFRalpha+ (fraction I) and ALDH-PDGFRalpha+ (fraction II) cells isolated from 3B / 2A-induced day 4 EBs.

[0026] [Figure 11] Analysis of GYPA expression in unsorted and sorted mesodermal populations. (A) qRT-PCR analysis of GYPA expression levels in 3B / 2A and 10B / 6A induced EBs at the indicated days of differentiation, t-test: **P<0.01 for the indicated samples (n=4). (B) QRT-PCR analysis of ALDH1A2, CYP26A1, and GYPA expression levels in ALDH+ (fraction IV) and CD235a+ (fraction III) fractions isolated from day 4 5B / 4A induced EBs. For all PCR analyses, expression values ​​were normalized to the housekeeping gene TBP. t-test: **P<0.01 (n=3). Error bars represent SEM.

[0027] [Figure 12] Optimizing ventricular differentiation through manipulation of mesoderm induction.

[0028] (A and B) CD235a in day 4 EBs after manipulation (days 1–3) with (A) activin A concentrations (2–20 ng / ml) in the presence of 10 ng / ml BMP4 or (B) BMP4 concentrations (3–20 ng / ml) in the presence of 12 ng / ml activin A. + Cells (left) and resulting CTNT in day 20 EBs + MLC2V + Flow cytometry analysis (n=6) of the percentage of cells (right). t-test: *P<0.05, **P<0.01 for the indicated samples. (C) Bar graphs (n=4) showing the average number of cells generated per well of a 6-well plate of EBs (day 20) induced with either 5B / 12A or 10B / 6A. t-test: P>0.05=ns, not significant. (D) CTNT at days 20 and 40 of culture in EB populations induced as indicated. + MLC2V + Flow cytometry analysis of cell percentages (n=3). t-test: P>0.05=ns, not significant. Error bars represent SEM.

[0029] [Figure 13]Characterization of atrial and ventricular cardiomyocytes derived from different mesodermal populations. (A) Flow cytometry analysis of the percentage of MLC2V+ cells in day 20 EBs induced under ventricular induction (VI), mixed induction (MI) and atrial induction (AI) conditions. t-test: **P<0.01 versus indicated samples. (B) Photomicrographs showing immunostaining for MLC2V in day 20 EB populations generated from AI and VI. Cells were co-stained with CTNT to identify all cardiomyocytes and DAPI to visualize all cells. Scale bars represent 100 μm. (C and D) QRT-PCR analysis of expression levels of (C) atrial and (D) pacemaker genes in NKX2-5+SIRPalpha+CD90- cells (n=4) isolated from day 20 EB populations induced as indicated and fetal tissue controls (n=6). t-test: *P<0.05, **P<0.01, VI vs. VI+RA; AI vs. AI+RA and for the indicated samples; ##P<0.01, FV vs. FA. (E) Flow cytometry analysis of the percentage of NKX2-5+SIRPalpha+ cells in day 20 EBs induced under either VI or AI conditions and treated with the indicated concentrations of RA (0.125-4 μM) on days 3-5 (n=3). (F-H) QRT-PCR analysis of expression levels of (F) atrial gene KCN5A, (G) ventricular genes MYL2, IRX4, and (H) atrial genes KCNJ3, CACNA1D, and NR2F2 in NKX2-5+SIRPalpha+CD90- cells isolated from different day 20 populations; t-test: *P<0.05, **P<0.01, for VI samples at each RA concentration (n=4). For all PCR analyses, expression values ​​were normalized to the housekeeping gene TBP. Error bars represent SEM. FV: fetal ventricular tissue, FA: fetal atrial tissue, ns: not significant.

[0030] [Figure 14]Characterization of atrial and ventricular cardiomyocytes derived from HES2 and MSC-iPS1 hPSCs. (A) Representative flow cytometry analysis of ALDH activity and CD235a expression in MSC-iPS1-derived EBs induced with 4B / 1A followed by induction with or without SB-431542 (SB) (days 3–5). (B–D) QRT-PCR analysis of expression levels of (B) total cardiomyocyte, (C) ventricular and (D) atrial genes in SIRP alpha+CD90- cells isolated from day 20 HES2-derived EB populations induced under ventricular (5B / 6A) or atrial (5B / 2A) conditions (days 1–3) and treated with either ROH, RA or DMSO (control) on days 3–5. t-test: *P<0.05, **P<0.01 vs. DMSO control, #P<0.05, ##P<0.01 vs. indicated samples (n=5). (E-G) QRT-PCR analysis of expression levels of (E) total cardiomyocyte, (F) ventricular and (G) atrial genes in SIRPalpha+CD90- cells isolated from day 20 MSC-iPS1-derived EBs induced under ventricular (4B / 4A) or atrial (4B / 1A+SB) conditions (days 1-3) and treated with either ROH, RA or DMSO (control) on days 3-5. t-test: *P<0.05, **P<0.01 vs. DMSO control, ##P<0.01 vs. indicated samples (n=5). For all PCR analyses, expression values ​​were normalized to the housekeeping gene TBP. Error bars represent SEM. SB: SB-431542 (Nodal / activin A / TGFβ inhibitor).

[0031] [Figure 15] A blueprint depicting the different differentiation pathways of cardiac cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0032] definition

[0033] The term "ventricular cardiomyocytes" as used herein refers to a population of cells enriched in ventricular cells or enriched in cells with ventricular cell characteristics. These include cardiomyocytes that express ventricular specific markers such as MYL2, IRX4, and / or elevated levels of NKX2-5, and / or exhibit electrophysiological properties of ventricular cells (e.g., action potentials).

[0034] As used herein, the term "atrial cardiomyocytes" refers to a population of cells enriched for atrial cells or enriched for cells with atrial cell-like properties, including cardiomyocytes that express atrial-specific markers, such as the atrial ion channel genes KCNJ3, NPPA, GJA5, and / or MYL7, and / or exhibit electrophysiological properties (e.g., action potentials) of atrial cells.

[0035] As used herein, the terms "cardiovascular mesoderm cells" and "cardiovascular mesoderm" refer to a population of mesoderm cells enriched for mesoderm cells that have an increased capacity for differentiation into cardiovascular cells relative to other mesoderm cells.

[0036] As used herein, the terms "ventricular mesoderm cells" and "ventricular mesoderm" refer to a population comprising mesoderm cells enriched for mesoderm cells that have increased capacity for differentiation into ventricular cardiomyocytes relative to other mesoderm cells, including mesoderm cells that are one or more of: ALDH-, RALDH2-CD235a+, CD235b+, and CYP26A1+.

[0037] As used herein, the terms "atrial mesodermal cells" and "atrial mesoderm" refer to a population that contains mesodermal cells that are enriched for mesodermal cells that have an increased capacity for differentiation into atrial cardiomyocytes relative to other mesodermal cells, including mesodermal cells that are one or more of ALDH+, RALDH2+, CD235a-, CD235b-, and CYP26A1-.

[0038] As used herein, the term "cardiomyocyte" refers to a cardiac lineage cell. Cardiac lineage cells typically express the pan-cardiac specific marker cTNT.

[0039] The term "pacemaker cell" as used herein refers to cardiomyocytes that have pacemaker activity and express sinoatrial node (SAN) cell specific markers.Pacemaker cells generally have a faster beating rate than ventricular cardiomyocytes.Pacemaker cells do not express NKX2-5.

[0040] The term "NKX2-5" used herein refers to the cardiac homeobox protein NKX2-5, which is encoded by the NKX2-5 gene in humans.The gene is involved in cardiac differentiation and is expressed in cardiomyocyte subtypes, such as ventricular cardiomyocytes.NKX2-5 expression can be measured, for example, by using an antibody specific for NKX2-5, or, for example, by using a NKX2-5 reporter construct.

[0041] As used herein, the term "BMP component" means any molecule, optionally any BMP or growth differentiation factor (GDF), or small molecule, that activates the receptor for BMP4, including, for example, BMP4 and / or BMP2.

[0042] As used herein, the term "BMP4" (e.g., gene ID: 652) refers to bone morphogenetic protein 4, e.g., human BMP4, as well as active conjugates and / or fragments thereof that can activate, e.g., BMP4 receptor signaling.

[0043] As used herein, the term "essentially free of pacemaker cells" refers to a population of cardiomyocytes in which pacemaker cells comprise less than 5% of the total cells, less than 1% pacemaker cells, less than 0.5% pacemaker cells, less than 0.1% pacemaker cells, less than 0.01% pacemaker cells, less than 0.001% pacemaker cells, or less than 0.0001% pacemaker cells, completely devoid of pacemaker cells, or pacemaker cells are undetectable in the population of cardiomyocytes via currently available detection methods. Without wishing to be bound by any theory, it is postulated that the presence of pacemaker cells in the population of ventricular cells may induce independent and separate contractions of the muscle when introduced into a patient.

[0044] As used herein, the term "activin component" refers to one or more components, or a composition comprising said components, that activate nodal signaling and optionally have activin A activity, such as activin A and / or nodal.

[0045] As used herein, the term "activin" or "ActA" refers to "activin A" (e.g., gene ID: 3624), e.g., human activin A, as well as active conjugates and fragments or small molecules thereof, that can activate nodal signaling.

[0046] The term "retinoic acid" or "RA" refers to retinoic acid.

[0047] The term "retinoic acid component" includes compounds that mediate the functions of vitamin A, such as all-trans RA (e.g., Sigma R2625), 9-cis RA (e.g., Sigma R4643), and retinol (e.g., Sigma R7632), as well as RA analogs (e.g., RAR agonists), such as the selective RAR alpha agonist AM580 (Tocris 0760), the selective RAR beta agonist AC55649 (Tocris 2436), and the selective RAR gamma agonist CD437 (Tocris 1549).

[0048] The term "embryoid body medium" as used herein refers to a culture medium that supports the formation of aggregates (e.g., floating aggregates of PSCs that have the ability to differentiate into cells of all three germ layers) or embryoid bodies of PSCs, and includes minimal media such as StemPro 34 (ThermoFisher), MesoFate™ (Stemgent), RPMI (ThermoFisher and other companies), HES medium (DMEM / F12 with KnockOut Serum Replacement, ThermoFisher and other companies), and, for example, BMP components, optionally BMP4, and further optionally a Rho-associated protein kinase (ROCK) inhibitor.

[0049] The term "embryoid body aggregation phase" as used herein refers to a period during which non-aggregated hPSCs are cultured, for example, using an embryoid body medium as described herein, and are treated with BMP components, and optionally with ROCK inhibitors and / or other components that result in aggregates such as embryoid bodies (e.g., aggregates of PSCs that can differentiate into cells of all three germ layers). Treatment with components may be simultaneous, overlapping, or separate. For example, a first component may be included in the medium, and a second component may be added to the medium during the embryoid body aggregation phase.

[0050] The term "mesoderm induction medium" supports the formation of cardiovascular mesoderm cells and can include culture media including minimal media, such as StemPro 34 (ThermoFisher), MesoFate™ (Stemgent), RPMI (ThermoFisher and other companies), etc. Mesoderm induction medium can include additional components, such as BMP components, optionally BMP4, activin components, optionally activin A, etc., and may also include other components such as bFGF. Depending on the desired fate of the cardiomyocytes generated from mesoderm, the different concentrations of each of the BMP components and activin components can be adjusted as taught herein.

[0051] The term "mesodermal induction phase" can refer to a period during which PSCs are cultured with mesodermal induction medium and, for example, treated with BMP and activin components, and optionally with FGF and / or other components, so that the PSCs differentiate into mesodermal cells. Treatment with BMP and activin components can be simultaneous, overlapping, or separate. For example, a first component can be included in the medium at the beginning of mesodermal induction, and a second component can be added to the medium during the mesodermal induction phase.

[0052] The term "cardiac induction medium" can include culture media that support the induction of cardiac progenitor cells from mesodermal cells, such as StemPro-34 minimal medium, including, for example, a WNT inhibitor, optionally IWP2, VEGF and / or optionally an activin / nodal inhibitor, and optionally SB-431542. Depending on the desired cell type, the cardiac induction medium may also include BMP components, retinoic acid, FGF inhibitors or FGF components. One embodiment of the cardiac induction medium (also referred to as standard cardiac induction medium) is StemPro-34 minimal medium containing 0.5 μM IWP2, 10 ng / ml VEGF, and optionally 5.4 μM SB-431542. Other minimal media that can be used include MesoFate™ (Stemgent) and RPMI (ThermoFisher and other companies).

[0053] The term "cardiac induction phase" can be used to describe the period during which mesodermal cells are induced to differentiate into cardiac progenitor cells when cultured with cardiac induction medium and are optionally treated with, for example, BMP components and RA, as well as FGF inhibitors or FGF components and / or other components that result in cardiovascular progenitor cells. The treatments may be simultaneous, overlapping, or separate. For example, a first component may be included in the medium and a second component may be added to the medium during the cardiac induction phase.

[0054] The term "basal medium" refers to a culture medium that supports the growth of cardiovascular progenitor cells and cardiomyocytes and can include minimal media, such as StemPro 34 (ThermoFisher), MesoFate™ (Stemgent), RPMI (ThermoFisher and other companies), and those that contain, for example, VEGF. An example of a basal medium is provided in Example 1.

[0055] The term "basal phase" can be used to refer to the period during which cardiovascular progenitor cells are cultured with basal medium and treated with VEGF and / or other components that result in cardiomyocytes. The treatments can be simultaneous, overlapping, or separate.

[0056] The term "incubating" can include any in vitro method of maintaining and / or growing a population of cells, including monolayer, bead, flask, or 3D culture, optionally with controlled ambient conditions, such as in an incubator, and optionally with passaging of the cells. In steps involving incubating cells with one or more components, the components may be added simultaneously or at different times for overlapping or separate periods of time. Factors may be added to the medium, for example, after initiating incubation of the cells in induction medium, or factors may be added to the medium before the medium is added to the cells. Additionally, cells may be washed between incubations, for example to reduce levels of components from previous incubations.

[0057] The term "culturing" can include any in vitro method of maintaining and expanding a population of cells through at least one cell division, including monolayer, bead, flask, or 3D culture, optionally under controlled ambient conditions, such as in an incubator.

[0058] As used herein, the term "enriched" means to include at least 50%, at least 60%, or at least 70% up to 100% enriched cell type. In one embodiment, enrichment is measured in day 20 cultures using the methods described herein.

[0059] As used herein, the term "subject" includes all members of the animal kingdom, such as mammals, and preferably refers to humans.

[0060] The terms "treat," "treating," "treatment," and the like as applied to cells include subjecting cells to any type of process or condition or subjecting cells to any type of manipulation or procedure.

[0061] The term "treatment" as used herein, when applied to a subject, refers to an approach aimed at obtaining beneficial or desired results, e.g., clinical results, and includes the application of medical procedures and interventions such as drugs or other products. In one embodiment, treatment refers to the administration of a product for the purpose of engraftment. Beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, reduction in the extent of disease, stabilization (i.e., not worsening) of a disease state, prevention of disease spread, delay or slowing of disease progression, amelioration or palliation of a pathology, and remission (partial or complete remission), which may be detectable or undetectable. "Treatment" can also mean prolonging survival compared to expected survival in the absence of treatment.

[0062] As used herein, the term "heart failure" refers to a condition in which the subject's heart cannot pump adequately to maintain a suitable flow of blood through the subject's body. A subject at risk of heart failure refers to a subject that has one or more characteristics known to precede heart failure. For example, a subject at risk of heart failure may have or have had coronary artery disease, previous myocardial infarction (heart attack), high blood pressure, atrial fibrillation, valvular heart disease, excessive alcohol intake, tobacco intake, obesity, sleep apnea, infection (viral and / or bacterial), cardiomyopathy, myocarditis, congenital heart defects, arrhythmia, and / or other diseases, such as, but not limited to, diabetes, hyperthyroidism, hypothyroidism, hemochromatosis and / or amyloidosis.

[0063] As used herein, the terms "myocardial infarction" and "MI" refer to an event in which blood flow to a portion of the heart is reduced or stopped, thereby causing the death of heart muscle cells due to lack of oxygen supply (ischemia) and resulting in damage to the heart muscle.

[0064] As used herein, the terms "administering," "introducing," and "implanting" are used interchangeably in the context of delivery of cells to a subject by a method or route that results in at least partial localization of the introduced cells at a desired site.

[0065] The term "pluripotent stem cell" or "PSC" as used herein refers to a cell that has the ability to differentiate into any one of the cell types characteristic of the three germ layers under different conditions, including embryonic stem cells and induced pluripotent stem cells. Pluripotent cells are characterized by their ability to differentiate into more than one cell type, for example, using nude mouse teratoma formation assay. Pluripotency is also demonstrated by the expression of embryonic stem (ES) cell markers. As used herein, pluripotent stem cells can include induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs).

[0066] In one embodiment, the term "embryonic stem cells" excludes stem cells involving the destruction of an embryo, such as a human embryo.

[0067] As used herein, the terms "iPSC" and "induced pluripotent stem cell" are used interchangeably and refer to pluripotent stem cells that have been artificially derived (e.g., by induced or complete reversal) from a non-pluripotent cell, typically an adult somatic cell, by inducing expression of one or more genes (e.g., but not limited to, SOX2 (Gene ID; 6657), KLF4 (Gene ID; 9314), cMYC (Gene ID; 4609), NANOG (Gene ID; 79923), POU4F1 / OCT4 (Gene ID; 5460) in combination with LIN28 / LIN28A (Gene ID; 79727)).

[0068] The cardiomyocytes prepared, enriched or isolated by the method of the present invention are derived from pluripotent stem cells.Patient's cells may be genetically modified before use, for example, through the introduction of genes that can control the state of differentiation before, during or after exposure to the differentiation factors described herein.The pluripotent stem cells suitable for use in the method described herein are derived from the patient's own tissue, which promotes the compatibility of the differentiated tissue graft derived from stem cells with the patient.

[0069] The term "embryonic stem cell" is used to refer to pluripotent stem cells of the inner cell mass of embryonic blastocysts (see, e.g., U.S. Patent Nos. 5,843,780 and 6,200,806). Such cells can also be obtained from the inner cell mass of blastocysts derived from somatic cell nuclear transfer (see, e.g., U.S. Patent Nos. 5,945,577, 5,994,619 and 6,235,970). The distinguishing characteristics of embryonic stem cells define the phenotype of the embryonic stem cells. Thus, a cell has an embryonic stem cell phenotype if it possesses one or more of the unique characteristics of embryonic stem cells that make the cell distinguishable from other cells. Exemplary distinguishing embryonic stem cell characteristics include, but are not limited to, gene expression profile, proliferation capacity, differentiation capacity, responsiveness to certain culture conditions, and the like.

[0070] As used herein, pluripotent stem cells may be genetically modified through the introduction of a vector that expresses a selection marker, such as Oct-4, under the control of a stem cell specific promoter, or a gene that can be upregulated to induce cardiomyocyte differentiation.Stem cells may be genetically modified with a marker or gene at any stage, so that the marker or gene is retained throughout any stage of culture.Markers may be used to purify or enrich the population of differentiated or undifferentiated stem cells at any stage of culture.

[0071] The term "pharmaceutical acceptable carrier" as used herein includes essentially chemically inert and non-toxic compositions that do not interfere with the effect of biological activity of pharmaceutical compositions. Examples of suitable pharmaceutical carriers include, but are not limited to, water, saline solution, glycerol solution, ethanol, N-(1(2,3-dioleyloxy)propyl)N,N,N-trimethylammonium chloride (DOTMA), dioleylphosphotidyl-ethanolamine (DOPE) and liposomes. Such compositions should contain a therapeutically effective amount of compound together with a suitable amount of carrier to provide a form for direct administration to a subject.

[0072] In the understanding of the scope of the present disclosure, the term "concentration" as used herein refers to the final concentration of a substance in a medium, such as BMP4, activin A, retinoic acid, etc. Unless otherwise indicated, the concentration is based on a mass / volume ratio.

[0073] As used herein, terms of degree, such as "substantially," "about," and "approximately," refer to a reasonable amount of deviation from the modified term such that the end result is not materially altered. These terms of degree should be interpreted as including a deviation of at least ±5% of the modified term, unless this deviation would negate the meaning of the word it modifies.

[0074] The recitation of numerical ranges by endpoints herein includes all numbers and fractions subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.90, 4, and 5). It should also be understood that all numbers and fractions thereof are considered to be modified by the term "about." Additionally, "a," "an," and "the" should be understood to include multiple referents unless the content clearly dictates otherwise. The term "about" means plus or minus 0.1 to 50%, 5 to 50%, or 10 to 40%, preferably 10 to 20%, and more preferably 10% or 15% of the referenced number.

[0075] Moreover, it is intended that the definitions and embodiments described in certain sections are applicable to other embodiments described herein that would be understood to be suitable by those skilled in the art.For example, in the following, different aspects of the invention are defined in more detail.Each aspect so defined can be combined with any other one or more aspects, unless expressly indicated otherwise.In particular, any feature indicated as preferred or advantageous can be combined with any other one or more features indicated as preferred or advantageous.

[0076] Aspects and embodiments

[0077] In one aspect, a method for producing a population of cardiomyocytes enriched in atrial cardiomyocytes is provided, comprising the steps of: i. incubating pluripotent stem cells in a suitable medium for generating aggregates and / or embryoid bodies; ii. further incubating stem cells in a suitable medium for mesoderm induction, said medium comprising at least a BMP component, optionally BMP4, and an activin component, optionally activin A, wherein the BMP component is provided in a ratio of 3:2 to the activin component; iii. further adding a retinoic acid component to the cells, said adding retinoic acid being added during mesoderm induction or cardiovascular lineage commitment stage; iv. continuing to grow the cells in a suitable medium to generate a population of cardiomyocytes, said population of cardiomyocytes being enriched in atrial cardiomyocytes. In some embodiments, the ratio of BMP to activin is 1.5:1.0 (or 3:2).

[0078] In some embodiments, the BMP component is BMP4 and the activin component is activin A, the BMP4 concentration is 3 ng / ml and the activin A concentration is 2 ng / ml. In some embodiments, the retinoic acid component is trans retinoic acid and is added at a concentration of 50 nm to 5 μM. In some embodiments, the retinoic acid component is added at a concentration of 500 nM.

[0079] In some embodiments, the BMP component and the activin component are added to the method on day 1. In some embodiments, the retinoic acid component is added to the method on day 3. In some embodiments, no additional BMP component is added to the medium on day 3 of the method.

[0080] In some embodiments, no FGF inhibitor is provided to the medium on day 3 of the method. In some embodiments, the cells produced by the method are used in an in vitro assay to screen for cardiac texicity that may be caused by potential therapeutic compounds. It is used in assays.

[0081] In one aspect, an isolated population of cardiomyocytes enriched in atrial cardiomyocytes is provided, comprising at least or about 50% atrial cardiomyocytes, at least or about 60% atrial cardiomyocytes, at least or about 70% atrial cardiomyocytes, at least or about 80% atrial cardiomyocytes, or at least or about 90% atrial cardiomyocytes, preferably obtained according to the method described herein.In one aspect, a method for producing a population of cardiomyocytes enriched in ventricular cardiomyocytes is provided, comprising the steps of: i. incubating pluripotent stem cells in a medium suitable for generating aggregates (embryoid bodies); ii. incubating the aggregated stem cells in a medium suitable for mesoderm induction, the medium comprising at least a BMP component, optionally BMP4, and an activin component, optionally activin A, the concentration of the activin component being higher than the concentration of the BMP component; iii. continuing to grow the cells in a suitable medium to generate a population of cardiomyocytes, the population of cardiomyocytes being enriched in ventricular cardiomyocytes. In some embodiments, the ratio of BMP to activin is about 0.3:1.0, about 0.5:1.0 (or 1:2), or about 0.8:1.0.

[0082] In some embodiments, the concentration of BMP and / or activin components is determined by measuring the level of CD235a and comparing this to the level of RALDH2.

[0083] In some embodiments, the concentration of the activin component is selected based on the concentration that results in preferentially more CD235a-expressing mesodermal cells compared to RALDH2-expressing mesodermal cells, and the BMP component is added to achieve a concentration lower than that of the activin component. In some embodiments, the BMP component is added to achieve optimal cardiogenesis from induced mesoderm.

[0084] In some embodiments, the BMP component is BMP4 and the activin component is activin A, the concentration of BMP4 is 3-20 ng / ml, the concentration of activin A is 4-20 ng / ml, and the concentration of activin A is greater than the concentration of BMP4. In some embodiments, the concentration of BMP4 is 10 ng / ml, and the concentration of activin A is 12 ng / ml.

[0085] In one aspect, an isolated population of cardiomyocytes enriched in ventricular cardiomyocytes is provided, comprising at least or about 30% ventricular cardiomyocytes, at least or about 40% ventricular cardiomyocytes, at least or about 50% ventricular cardiomyocytes, at least or about 60% ventricular cardiomyocytes, at least or about 70% ventricular cardiomyocytes, at least or about 80% ventricular cardiomyocytes, or at least or about 90% ventricular cardiomyocytes, preferably obtained according to the method described herein. In one embodiment, the isolated population of cardiomyocytes enriched in ventricular cardiomyocytes is essentially free of pacemaker cells. In a preferred embodiment, the isolated population of cardiomyocytes enriched in ventricular cardiomyocytes is devoid of pacemaker cells.

[0086] The isolated population of cardiomyocytes according to the present invention may be used in a method for screening for potential cardiotoxicity of potential therapeutic active agents for use in the treatment of cardiovascular and any other disorders. For example, they provide a source of cells that can be used in drug screening for cardiovascular applications; provide a source of cells that can be used for therapeutic purposes, such as to restore cardiac function, repair an ischemic heart and / or regenerate coronary vasculature; can be used for tissue engineering purposes where components of the heart or coronary vasculature are required; and can serve as a research tool for the study of cardiovascular development and disease. The isolated population of cardiomyocytes used for screening active agents according to the method of the present invention may include, for example, a population of cardiomyocytes enriched for ventricular cardiomyocytes. Such a population of ventricular cardiomyocytes optionally includes a population that is essentially free of pacemaker cells or devoid of pacemaker cells. The isolated population of cardiomyocytes used for screeing active agents according to the method of the present invention may include, for example, a population of cardiomyocytes enriched for ventricular cardiomyocytes. Such a population of ventricular cardiomyocytes may include, optionally, a population that is essentially free of pacemaker cells or devoid of pacemaker cells. The isolated population of cardiomyocytes used for screeing active agents according to the method of the present invention may include, for example, a population of cardiomyocytes enriched for ventricular cardiomyocytes. The population may also include a population of cultured atrial cardiomyocytes. Such methods of screening or evaluating the potential cardiotoxicity of a test compound or agent involve exposing a population of cardiomyocytes according to the invention to a compound to be tested for cardiotoxicity. The effects evaluated include changes in viability, contractility, membrane potential and / or other functions of the cells.

[0087]

[0088] The population of cardiomyocytes and cardiomyocyte precursor cells produced using the method of the present invention can be used for transplantation, cell therapy or gene therapy.For example, the present invention provides differentiated cells produced using the method of the present invention that can be used for therapeutic purposes, such as in a method of treating a subject in need of cardiac repair.For example, therapeutic repair can involve fully or partially restoring cardiac function in a subject in need of cardiac repair, such as a subject suffering from a cardiac disease or condition.

[0089] Another aspect of the present invention is a method for treating or preventing cardiac disease or condition.Cardiac disease is typically associated with a decrease in cardiac function, including, but not limited to, conditions such as myocardial infarction, cardiac hypertrophy and cardiac arrhythmia.In this aspect of the present invention, the method comprises introducing the isolated differentiated ventricular cardiomyocytes and / or cells that can differentiate into ventricular cardiomyocytes of the present invention into a subject in need of cardiac repair.The isolated cardiomyocytes can be transplanted into the damaged cardiac tissue of the subject.Ideally, the method results in the recovery of some or all cardiac function in the patient.

[0090] In one aspect, a method of treating a subject having heart failure is provided, comprising administering to the subject a population of ventricular cardiomyocytes as described herein. In some embodiments, the subject has suffered a myocardial infarction. In some embodiments, the myocardial infarction is in the patient's ventricle and the population is as described herein.

[0091] In one aspect, a population of ventricular cardiomyocytes as described herein is provided for use in treating a subject having or at risk of heart failure. In one aspect, a use of a population of ventricular cardiomyocytes as described herein in the preparation of a medicament for treating a subject having or at risk of heart failure is provided.

[0092] In yet another aspect of the invention, there is provided a method of repairing cardiac tissue comprising introducing isolated ventricular cardiomyocytes or cardiac progenitor cells of the invention and / or cells capable of differentiating into ventricular cardiomyocytes when treated using the methods of the invention into damaged cardiac tissue of a patient.

[0093] The patient may be a patient suffering from a cardiac disease or condition. In the method of repairing cardiac tissue of the present invention, the isolated cardiomyocytes may be transplanted into the damaged cardiac tissue of the patient. Ideally, the method results in the restoration of at least some cardiac function in the patient.

[0094] In one embodiment, the ventricular cardiomyocytes disclosed herein are administered to a subject during the acute phase following myocardial infarction or during the chronic phase of heart failure. The cells are administered to the site of injury in the ventricle by either direct injection or catheter-based delivery. The cells may be formulated with a pharma- ceutically acceptable carrier, hydrogel, or scaffold, for example, to aid in the placement, survival, and / or engraftment of the cells in the tissue. Dosage ranges for the cells can include, for example, about 500 million to 2 billion cells per dose. The cells can be administered to the subject in single or multiple doses at one or more time points to treat the subject.

[0095] The present invention preferably provides a myocardial model for testing the ability of stem cells differentiated into cardiomyocytes or cardiac progenitor cells using the method of the present invention to restore cardiac function. To test the efficacy of cardiomyocyte transplantation in vivo, a reproducible animal model with measurable parameters of cardiac function is important. The parameters used should clearly distinguish between control and experimental animals so that the effect of transplantation can be fully determined [see, for example, Palmen et al. (2001), Cardiovasc. Res. vol. 50, pp. 516-524]. PV relationship is an indicator of the pumping ability of the heart and can be used as a readout of altered cardiac function after transplantation.

[0096] In one embodiment, a method for detecting atrial mesoderm in a population of cells is provided, comprising detecting RALDH2, the presence of which is indicative of atrial mesoderm.In one embodiment, a method for detecting ventricular mesoderm in a population of cells is provided, comprising detecting CD235a and / or CYP26A1, the presence of which is indicative of ventricular mesoderm.

[0097] The present invention provides a method for identifying atrial or ventricular mesoderm based on the expression of ALDH, preferably RALDH2, and / or CD235a and / or CD235b, and / or CYP26A1, respectively. More specifically, they can be used to identify secretory factors produced by mesoderm cells that affect cardiomyocyte proliferation, survival, function and differentiation of atrial or ventricular cell populations. For example, the present invention provides a system for identifying atrial or ventricular cardiomyocyte populations, both for understanding the differentiation of atrial and ventricular mesoderm at the molecular level and for identifying new drug targets (e.g., signaling pathways) that modulate differentiation.

[0098] According to one or more of the embodiments disclosed herein, retinoic acid (RA) drives lineage commitment to atrial cardiomyocytes within a specific developmental time window, and application of RA to mesoderm on days 3-5 drives lineage commitment to atrial cardiomyocytes. RA concentration range: 50 nM-5 uM. Source of RA: all-trans RA, retinoic acid receptor (RAR) agonists (AM580 for alpha, AC55649 for beta, CD437 for gamma), agonist concentrations: 3-300 nM for AM580; 0.025-2.5 uM AC55649; 0.05-5 uM CD437.

[0099] RALDH2 (retinal dehydrogenase, or Aldefluor) is a marker for atrial mesoderm. + The percentage of cells is monitored by using the aldefluor assay to optimize atrial differentiation. Analysis days: days 2-6.

[0100] Early mesoderm induction using activin A and BMP4 on day 1 was followed by RALDH2 on day 4. + Determine the percentage of mesodermal cells. Induction conditions are low BMP (1-5 ng / mL BMP) and low activin A (0.1-4 ng / ml), most commonly 3 ng / mL BMP / 2 ng / mL activin A (3B / 2A) is used.

[0101] The functionality of RALDH2 was demonstrated by treatment with retinol (ROH) for days 3-5, which is sufficient to induce the atrial phenotype (retinol is converted to RA by RALDH2, which commits the atrial phenotype). Glycophorin A (CD235a) is a marker of the ventricular mesoderm. CD235a is exclusively expressed in the ventricular mesoderm and RALDH2 + Not present in atrial mesoderm. + The cells do not express RALDH2. + Cells express CYP26A1, an enzyme that degrades RA, to antagonize RA signaling and ensure establishment of the ventricular phenotype. Analysis days: days 2-6.

[0102] Early mesoderm induction using Activin A and BMP4 on day 1 was followed by CD235a on day 4. + Determine the percentage of mesodermal cells. Induction conditions are high BMP (5-20 ng / mL BMP) and high activin (6-20 ng / mL), most commonly 10 ng / mL BMP / 12 ng / mL activin A (10B / 12A) is used. CD235a in retinol (ROH) on days 3-5. + Treatment of the cells is not sufficient to induce an atrial phenotype (these cells cannot convert retinol to RA and therefore the cells develop into a ventricular phenotype). + The cells are MLC2V + It gives rise to a population highly enriched in ventricular cardiomyocytes.

[0103] Ventricular and atrial cardiomyocytes are derived from two distinct mesodermal subpopulations. Ventricular differentiation is initiated from CD235a+ cells at day 4 and MLC2V+ cells at day 20. + / CTNT + Atrial differentiation is monitored by the appearance of AF+ cells at day 4 and MLC2v cells at day 20. - / CTNT + The day 20 population derived from ventricular mesoderm (10B / 12A) had a higher percentage of MLC2v cells than those derived from atrial mesoderm (3B / 2A). + Contains ventricular cardiomyocytes.

[0104] Gene expression and single-cell patch clamp analyses demonstrated that the day 20 population generated by RA treatment from atrial mesoderm (3B / 2A+RA) contained a higher percentage of atrial cardiomyocytes than the day 20 population generated by RA treatment from ventricular mesoderm (10B / 12A+RA).

[0105] Appropriate mesodermal subpopulations need to be lineaged to enrich for the desired cardiomyocyte subtype. Improved protocol for lineage commitment of ventricular cardiomyocytes for cell replacement therapy after myocardial infarction. CD235a + Ventricular mesoderm (10B / 12A) is a region lacking pacemaker cells, called MLC2v + It gives rise to a highly enriched population of ventricular cardiomyocytes, which results in a lower autonomous beating rate compared to other heterogeneous cardiomyocyte populations.

[0106] These are desirable features for cell replacement therapy after myocardial infarction, because mixed cell populations containing contaminating pacemaker cells and with fast autonomous beating rates can cause life-threatening arrhythmias. We propose that our new protocol for lineage commitment of ventricular cardiomyocytes is superior to previous protocols that generated mixed populations of ventricular and pacemaker cells. EXAMPLES

[0107] Methodology and Results

[0108] Human pluripotent stem cell lines can be cultured as previously described (e.g., Kennedy et al., 2007). For differentiation into cardiac lineages, established protocols such as those described in Kattman et al., 2011 can be used. Various modifications to the procedure are possible, such as those described in WO2016131137. In one embodiment, 80% confluent hPSC cultures can be dissociated into single cells, suspended in StemPro-34 medium containing 1 ng / mL BMP4 and 10 μM ROCK inhibitor, and incubated on an orbital shaker for 18 hours to generate embryoid bodies (EBs). The next day (day 1 of differentiation), EBs can be transferred to mesoderm induction medium, i.e., StemPro-34 containing a set concentration of BMP4 and 5 ng / ml bFGF in addition to a set concentration of activin A, as further described herein. On day 3 of differentiation, EBs may be washed once with IMDM and suspended in cardiac induction medium, which in one embodiment may comprise StemPro-34 containing 0.5 μM IWP2, 10 ng / ml VEGF, and optionally 5.4 μM SB-431542 (SB, an Activin / Nodal / TGFβ inhibitor). Cardiac induction medium may also optionally contain retinoic acid (RA) or RA components as further described herein.

[0109] Retinoic acid signaling directs lineage commitment of hESCs to atrial-like cardiomyocytes

[0110] To determine whether retinoic acid signaling could drive atrial fate commitment in hPSC-derived cardiac populations generated using our embryoid body (EB)-based protocol, all-trans retinoic acid (RA) was added to differentiation cultures at four different time points representing the following developmental stages: mesoderm induction (day 3), cardiovascular lineage commitment (day 5), cardiac progenitor development (day 7) and the emergence of contractile cardiomyocytes (day 9) (Kattman et al., 2011) (Figure 1A). The use of a HES3 NKX2-5:GFP reporter hESC line for these experiments allowed us to monitor and quantify cardiovascular development and to isolate GFP+ cardiomyocytes. At day 20 of culture, GFP+SIRPA+CD90- cardiomyocytes were isolated from the differentiated populations and analyzed by RT-qPCR for the expression of genes indicative of atrial and ventricular development (Figures 1B-D and 8B-E).

[0111] Neither RA treatment significantly altered the levels of expression of the total cardiomyocyte marker CTNT, pointing to comparable cardiomyocyte content in the different populations (Figure 1B). Addition of RA at days 3 and 5 resulted in a significant reduction in the expression of the ventricular-specific gene MYL2 and upregulation of the atrial ion channel gene KCNJ3 (Figure 1C), suggesting a change in cardiomyocyte fate in the day 20 population. Interestingly, addition of RA at later stages (days 7 and 12) had no effect on the expression of these genes. Analysis of additional chamber-specific markers showed that cardiomyocytes generated from RA-treated mesoderm at day 3 also expressed lower levels of ventricular markers IRX4 and MYH7 than the untreated group, whereas an inverted pattern was observed for the atrial markers NR2F2, TBX5, NPPA, and MYL7 as well as the atrial-specific ion channels CACNA1D, KCNA5, and GJA5 (Figures 1D and 8C-E). Analysis of control fetal tissues verified the atrium and ventricle expression patterns of these distinct genes. Flow cytometry and immunostaining analysis of cardiomyocyte populations generated from RA-treated mesoderm on day 3 confirmed the qRT-PCR expression patterns and showed a higher expression level of MLC2V in populations generated from RA-treated mesoderm on day 3 compared to those generated from untreated control mesoderm. + Dramatic reduction in the proportion of cells and COUPTFII + showed a much higher frequency of cells (Figure 1E-H).

[0112] Taken together, these findings strongly suggest that RA signaling induces a cardiac fate change in hPSCs, promoting the generation of atrial cardiomyocytes at the expense of the ventricular lineage. Moreover, they show that this effect of RA is restricted to an early developmental window, i.e., days 3–5 of differentiation, which corresponds to a mesodermal state of differentiation.

[0113] To further characterize the RA response, populations from days 2 to 6 of differentiation were next analyzed for expression of the three RA receptor (RAR) isoforms: RAR-alpha, -beta, -gamma (RARA, RARB, and RARG, respectively, in Figure 8F). All three were expressed during the response stage, suggesting that the RA response may be mediated through all of these (Figure 8F). To test this, receptor-specific agonists AM580 for alpha, AC55649 for beta, or CD437 for gamma were added in place of RA to day 3 cultures. Addition of each agonist significantly increased the CTNT at day 20. + This led to reduced MYL2 expression in the population, suggesting that signaling through all receptor isoforms can mediate fate changes (Figures 8G and 8H).

[0114] In some embodiments, RA may be added at a concentration of about 0.05 μM to about 5 μM. In one embodiment, the concentration of RA is 500 nM (0.5 μM). In one embodiment, the concentration of RA added is 0.05 μM to 0.01 μM. In one embodiment, the concentration of RA added is 0.01 μM to 0.1 μM. In some embodiments, an RA component is added. In some embodiments, the RA component is a retinoic acid receptor (RAR) agonist. In some embodiments, the RAR agonist is an agonist for the alpha receptor. In some embodiments, the RAR agonist is AM580. In some embodiments, the AM580 RAR agonist is added at a concentration of about 3 nM to about 300 nM. In some embodiments, the RAR agonist is an agonist for the beta receptor. In some embodiments, the RAR agonist is AC55649. In some embodiments, AC55649 is added at a concentration of about 0.025 μM to about 2.5 μM. In some embodiments, the RAR agonist is an agonist for a gamma receptor. In some embodiments, the RAR agonist is CD437. In some embodiments, the CD437 RAR agonist is added at a concentration of about 0.05 μM to about 5 μM.

[0115] RALDH2 and CYP26A1 expression identifies mesodermal subpopulations

[0116] If atrial fate lineage commitment is mediated through autocrine RA signaling, the mesodermal populations giving rise to these cardiomyocytes should display RALDH activity. To test this, we analyzed PDGFRalpha mesoderm induced in our standard conditions (10 ng / mL BMP4 and 6 ng / mL activin A (10B / 6A)) on different days using an adefluor assay that detects the activity of all aldehyde dehydrogenases (ALDH), including the three retinaldehyde dehydrogenases, RALDH1, -2, and -3 (Jones et al., 1995). These analyses revealed the presence of a small ALDH+PDGFRalpha+ population on days 4 and 5 of differentiation (Figure 2A), suggesting that a subpopulation of mesoderm at these stages may have the capacity to synthesize ALDH.ALDH + PDGFR Alpha + In an attempt to increase population size, the effect of varying the concentrations of Activin A and BMP4 during the mesoderm induction step was tested. Reducing the amount of Activin A in the presence of a constant concentration of BMP4 (10 ng / mL) reduced ALDH1 expression on day 4 of differentiation. + PDGFR Alpha + This led to a large increase in population size (Figure 2B). However, this increase was attributable to the low amount of CTNT produced. + Associated with a decrease in the proportion of cardiomyocytes, these changes suggested that they promoted a non-cardiac fate. Since we have previously shown that the ratio of activin A and BMP4 signaling is important for maintaining optimal cardiac differentiation potential (Kattman et al., 2011), we next investigated the mechanism by which ALDH expression was maximal. + PDGFR Alpha + The concentration of BMP4 was varied in the presence of an amount of activin A (2 ng / mL) that induces the ALDH population. Reducing the BMP4 concentration from 10 ng / mL to 3 ng / mL (3B / 2A) reduced the ALDH + PDGFR Alpha + Although it had no effect on population size, it did affect the CTNT produced on day 20. +The frequency of cells was increased (Figure 2C). Comparable cell numbers were obtained from 3B / 2A and 10B / 6A cultures, indicating that this manipulation did not significantly affect total cardiomyocyte production (Figure 9A).

[0117] Analysis of 3B / 2A-induced cultures revealed large PDGFRalpha expression on day 3 of differentiation. + Emergence of mesodermal population, followed by ALDH on day 4 + PDGFR Alpha + The occurrence of ALDH clusters was revealed (Figure 2D). + PDGFR Alpha + The population size increased until day 5 and then began to decrease on day 6. Molecular analysis showed that expression of RALDH2 (ALDH1A2) increased strongly on days 2–3 of differentiation and then decreased over the next 7 days in the 3B / 2A-induced group (Figure 2E). Cells induced with 10B / 6A expressed significantly lower levels of ALDH1A2 on days 3 and 4, and a smaller proportion of ALDH1A2 in this group. +The expression levels of the other RALDH isoforms (ALDH1A1 and ALDH1A3) were significantly lower than ALDH1A2 and did not differ between the two populations (Figure 9B). T(BRACHYURY) and MESP1 showed similar temporal expression patterns in both 10B / 6A- and 3B / 2A-induced populations, indicating that the kinetics of mesoderm induction did not differ dramatically between the two groups (Figure 9C). In developing embryos, the boundaries of RA activity and the duration of signaling are established by a balance between localized agonist synthesis and degradation (Cunningham and Duester, 2015; Rydeen and Waxman, 2014). To determine whether this balance is played out in hPSC differentiation cultures, we next analyzed the two populations for expression of CYP26A1, a member of the cytochrome P450 family enzyme involved in RA degradation. These analyses revealed striking differences between the two groups, with 10B / 6A-induced cells at day 3 exhibiting dramatically higher expression levels than any other 10B / 6A- or 3B / 2A-induced population (Figure 2E). Together, these findings support the interpretation that the combination of 3B / 2A and 10B / 6A induces distinct mesodermal populations that are distinguished by the expression of ALDH1A2 and CYP26A1.

[0118] Retinol commits ALDH+ mesoderm to atrial fate

[0119] ALDH + To determine whether cells can synthesize RA, ALDH + PDG-FR Alpha + and ALDH - PDGFR Alpha + Fractions were isolated from the day 4 3B / 2A-induced population, and cells were cultured as aggregates in retinol (ROH), RA, or DMSO (control) for 24 h (Figures 3A and 3B). + After an additional 15 days of culture, all groups had a high percentage of CTNTs.+ The untreated control contained MLC2V cells and demonstrated efficient cardiomyocyte differentiation (Figure 3D). + The 3B / 2A-induced mesoderm generated a population of cardiomyocytes that contained IRX4 cells and expressed IRX4, demonstrating that, without RA signaling, the 3B / 2A-induced mesoderm has some ventricular cardiac differentiation capacity (Figures 3E and 3F). After treatment with ROH, ALDH + Mesoderm expressed a lower frequency of MLC2V compared to untreated controls. + The ROH- and RA-treated ALDH1 expression increased the expression of IRX4 and KCNJ3 in the control rats, generating an atrial-like cardiomyocyte population with lower levels of IRX4 expression and elevated levels of KCNJ3 expression (Figures 3E-3G). + PDGFR Alpha + The expression patterns in the derived populations were similar, with ALDH + These results strongly suggest that cells can synthesize RA from ROH.

[0120] Strikingly, a similar response to ROH was observed in ALDH− cells (Figures 3E-3F), despite the lack of ALDH1A2 expression at the time of isolation (Figures 3B and 3C). This response was likely due to the fact that the majority of the ALDH− derived population became ALDH+ during the 24-h aggregate culture (Figure 10A), rendering the cells responsive to ROH. Interestingly, a decrease in aldefluor staining was observed in the ALDH+ derived population over the same 24-h period, highlighting the dynamic nature of ALDH activity (RALDH2 expression) within the mesodermal population.

[0121] Together, these findings demonstrate that 3B / 2A induces ALDH+PDG-FRalpha+(RALDH2+) mesoderm that can respond to ROH and generate atrial-like cardiomyocytes, supporting the idea that this fate lineage commitment is mediated via autocrine RA signaling.

[0122] Expression of CD235a marks the mesoderm that gives rise to ventricular cardiomyocytes. It is contemplated herein that CD235b may replace CD235a as a marker of mesoderm that gives rise to ventricular mesoderm due to the similarity and / or identity of the amino acid sequences of at least the N-terminal regions of glycophorin B and glycophorin A.

[0123] To be able to monitor the development of AYP26A1 expressing mesoderm (VM) that gives rise to ventricular cardiomyocytes, we began searching for a surface marker in this population that would allow us to distinguish it from ALDH+ mesoderm. Through a prior screening against anti-CD antibody arrays (http: / / www.ocigc.ca / antibody / ), we found that glycophorin A (CD235a) is expressed in a subset of cardiac PDGFRalpha+ cells at day 5 induced with 10B / 6A (data not shown). Analysis of the 10B / 6A and 3B / 2A induced populations revealed that the CD235a+ population increased (>60%) within the next 24 hours, before decreasing over the following 48 hours. A small proportion of ALDH detected at day 5 was positive for CD235a+. + The cells are CD235a - And ALDH + and CD235a + In the 3B / 2A-induced population, only a small amount of CD235a + Only GYPA (glycophorin A) cells were detected on day 4. qRT-PCR analysis revealed upregulation of GYPA (glycophorin A) expression on day 3 of differentiation in the 10B / 6A-induced group (Figure 11A). Expression levels declined drastically over the next 24 h and remained low over the period of analysis. Only low levels of expression were detected in the 3B / 2A-induced population. Based on these findings, we hypothesize that glycophorin A is expressed in mesoderm that contributes to the ventricular cardiomyocyte lineage.

[0124] To test the utility of CD235a for the isolation of ventricular progenitor cells, an induction strategy using moderate concentrations of BMP4 and activin A (5 ng / mL BMP4 and 4 ng / mL activin A [5B / 4A]) was used to identify CD235a + and ALDH + A day 4 population was generated that contained both CD235a and CD235a subpopulations (Figure 4B). + ALDH - and CD235a - ALDH + Both fractions were isolated and the cells were cultured as aggregates. qRT-PCR analysis of the sorted fractions demonstrated that ALDH1A2 upregulates CD235a - ALDH + CD235a in cells + ALDH - The results showed that MLC2V was expressed at a higher level than in MLC2V cells (Figure 11B). The expression levels of GYPA and CYP26A1 were not significantly different between the two, likely due to the fact that the fractions were isolated on day 4, past the peak expression of these genes. In the absence of ROH and RA, both fractions generated ventricular-like cells (Figures 4C-4E). However, MLC2V + The percentage of cells and expression of IRX4 were CD235a - ALDH + CD235a than in derivatives + ALDH - The opposite pattern was observed for the atrial genes KCNJ3 and NR2F2 (Figure 4F). - ALDH + is low frequency MLC2V + Cells expressed low levels of IRX4 and elevated levels of NPPA, KCNJ3, and NR2F2, giving rise to an atrial-like cardiomyocyte population (Figures 4D-4F). In contrast, CD235a + ALDH - The cells showed no response to ROH and no response to ALDH + We demonstrated that MLC2V cells are unable to synthesize RA in the absence of RA. As expected, both mesodermal populations responded to RA and- Taken together, these findings suggest that CD235a expression is a signaling pathway that mediates the expression of CD235a - ALDH + We demonstrate that CD235a marks a mesoderm population with the capacity to differentiate into ventricular cardiomyocytes that fails to generate atrial cells in response to ROH, a feature that distinguishes it from mesoderm. These findings also indicate that CD235a, as indicated by differential expression of ventricular and atrial genes in cardiomyocyte populations generated in the absence of RA signaling, is a signaling pathway that is essential for differentiation into ventricular cardiomyocytes. + and ALDH + It also suggests that the mesoderm populations are already patterned to their respective fates.

[0125] Optimization of ventricular cardiomyocyte differentiation

[0126] Although induction with 10B / 6A favors the generation of ventricular cardiomyocytes, the mesoderm generated under these conditions often contains a small percentage of ALDH+ cells and gives rise to a CTNT+ population containing a variable percentage (40%-60%) of MLC2V+ cells. To further optimize the generation of ventricular cardiomyocytes, we monitored the size of the CD235a+ fraction in day 4 EB populations induced with different concentrations of Activin A and BMP4 and compared this to the frequency of MLC2V+CTNT+ cells at day 20 (Figure 5A and Figure 5B). Increasing the concentration of Activin A from 2 ng / ml to 12 ng / ml in the presence of a constant amount of BMP4 (10 ng / mL) led to an increase in the size of the CD235a+ population at day 4, elimination of the ALDH++ population, and an increase in the percentage of MLC2V+CTNT+ cells (Figure 5A).

[0127] Next, the most frequent MLC2V + CTNT + The concentration of BMP4 was varied (3-20ng / mL) relative to the amount of activin A (12ng / mL) to generate CD235a cells. + Although it had little effect on population size, it did affect ventricular lineage commitment. The day 20 population generated from EBs induced with the highest concentration of BMP4 (20 ng / mL) had the lowest frequency of MLC2V+ CTNT + While EBs induced with a low concentration of BMP4 (5 ng / mL [5B / 12A]) produced the highest frequency of these cardiomyocytes (80% ± 5%) (Figure 5B and Figure 13B). Cultures induced with 5B / 12A and 10B / 6A yielded comparable cell numbers, with no loss in total cell yield, suggesting that MLC2V + CTNT + This indicates that enrichment of cells was obtained (Figure 12C).

[0128] It is worth noting that the optimal concentrations of Activin A and BMP4 depend on the activity of a particular lot of cytokine. Given this, these titrations need to be repeated with each new lot of cytokine to determine the optimal concentrations. To determine whether time in culture can affect the MLC2V+ content of hPSC-derived cardiomyocyte populations as reported (Burridge et al., 2014), we compared day 20 and day 40 populations generated from EBs induced with 3B / 2A, 10B / 6A, and 5B / 12A. As shown in Figure 13B, similar percentages of MLC2V+CTNT+ cardiomyocytes were detected at both time points in each population, demonstrating that extended culture time did not affect ventricular content under these conditions. Taken together, these findings indicate that induction of a CD235a+ population at day 4 is a prerequisite for the generation of a population highly enriched in MLC2V+CTNT+ cardiomyocytes. However, they also show that the size of this population does not necessarily predict the percentage of MLC2V+ cells on day 20 of culture. 5B / 12A-derived EB populations contained a high percentage of CD235a+ cells and no ALDH+ cells (Figure 5C), whereas those induced with 3B / 2A had a high frequency of ALDH+ cells and no CD235a + When lineage-committed (days 3–5) in the absence or presence of ROH or RA and cultured for an additional 15 days, both populations generated CTNTs. + They showed similar cardiac differentiation potential as measured by cell frequency (FIG. 5D).

[0129] 3B / 2A-induced EBs respond to ROH and MLC2V + 5B / 12A-induced EBs generated an atrial-like cardiomyocyte population characterized by loss of ROH cells, reduced expression of IRX4, and up-regulated expression of KCNJ3 and NR2F2 (Figures 5E-5G). In contrast, 5B / 12A-induced EBs did not respond to ROH and up-regulated ALDH + As expected, RA treatment was able to induce an atrial-like cardiomyocyte phenotype from this mesoderm.

[0130] The conditions used to optimize ventricular differentiation were consistent with the NKX2.5 expression levels typically detected in these cultures. - To determine whether NKX2-5-GFP affected the proportion of sinoatrial node pacemaker-like cells ( Birket et al., 2015 ; Protze et al., 2017 ), - Populations were analyzed for the presence of NKX2-5-GFP cells. As shown in Figure 5H, populations generated from optimized 5B / 12A-induced EBs showed significantly fewer NKX2-5-GFP cells than those derived from 10B / 6A-induced (Figure 1E) and 3B / 2A-induced EBs. - CTNT + cell NKX2-5-GFP expression in 5B / 12A-induced EBs was associated with a significant decrease in the spontaneous beating rate of 5B / 12A-induced EBs compared to 3B / 2A-induced EBs (Figure 5I). Consistent with our previous findings (Protze et al., 2017), RA treatment reduced the expression of NKX2-5-GFP in the induced population. - It had no effect on the proportion of cells (Figure 5J).

[0131] Taken together, 5B / 12A has a high proportion of CD235a + These findings indicate that the ventricular mesoderm contains ventricular cells, gives rise to a population highly enriched for ventricular cardiomyocytes, and commits to atrial cardiomyocytes and a subpopulation of mesoderm that is devoid of SANPLC. This subpopulation may also be referred to as ventricular mesoderm.

[0132] In some embodiments, optimization of ventricular differentiation results in enrichment of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% ventricular cardiomyocytes as measured in cultures at day 20 using the methods described herein. In some embodiments, the population is essentially free of pacemaker cells. In some embodiments, the population is devoid of pacemaker cells.

[0133] In some embodiments, the method of optimizing ventricular differentiation optimizes the generation of ventricular mesoderm by adding optimized concentrations of BMP and activin components. In some embodiments, the BMP component is BMP4 and the activin component is activin A. In some embodiments, BMP4 is added at a concentration of 3ng / ml to 20ng / ml. In some embodiments, activin A is added at a concentration of 4ng / ml to 20ng / ml. In preferred embodiments, activin A is added at a higher concentration than BMP4. In some embodiments, BMP4 is added at a concentration of 10ng / ml and activin A is added at a concentration of 12ng / ml. In some embodiments, the BMP and activin components are added on day 1 of the method. In some embodiments, the concentration of the BMP and / or activin components is determined by measuring the presence or amount of CD235a. In some embodiments, the concentration of the BMP and / or activin components is determined by measuring the presence or amount of RALDH2. In some embodiments, the concentration of BMP component and / or activin component is determined by measuring the level of CD235a and comparing it with the level of RALDH2.In ​​some embodiments, the concentration of activin component is selected based on the concentration that preferentially results in more mesodermal cells expressing CD235a compared to the mesodermal cells expressing RALDH2, and the BMP component is added at a lower concentration than the concentration of activin component.In some embodiments, the concentration of BMP component is selected based on the concentration that preferentially results in more CD235a compared to RALDH2, and the activin component is added at a higher concentration than the concentration of BMP component.

[0134] Characterization of cardiomyocytes generated from different mesoderm To further study the cardiac differentiation capacity of the different mesodermal populations, we isolated day 20 NKX2-5+SIRPalpha+CD90- cardiomyocytes generated from EBs induced with our original cytokine combination (10B / 6A; mixed induction MI) or combinations optimized for ventricular (5B / 12A; ventricular induction VI) or atrial (3B / 2A; atrial induction AI) fates. As expected, expression levels of CTNT were similar among the sorted populations (Figure 6A). Cardiomyocytes generated from VI EBs expressed significantly higher levels of genes associated with ventricular myocytes, such as MYL2, IRX4 and MYH7, than cardiomyocytes derived from MI or AI EBs (Figure 6B). The population derived from VI EBs had the highest frequency of MCL2V+ cardiomyocytes (80%±2% from VI EBs, 56%±4% from MI EBs, and 25%±5% from AI EBs), suggesting that the enhanced ventricular expression profile was due, in part, to an enriched frequency of ventricular-like cardiomyocytes (Figure S13A). The difference in MLC2V content of the cardiomyocyte populations was confirmed by immunostaining analysis (Figure S13B).

[0135] Cardiomyocytes generated from VI and AI EBs treated with RA (VI+RA and AI+RA, respectively) showed elevated levels of expression of all analyzed atrial genes compared to those isolated from non-treated EBs (Figure 6C and Figure 13C). Expression levels of KCNA5, KCNJ3, NR2F2, and CACNA1D in cells from AI+RA were as high as or higher than those in fetal atrial tissue (Figure 6C). Notably, their expression levels were significantly higher than those detected in myocytes generated from VI+RA EBs. In contrast, other atrial genes such as GJA5, NPPA, and MYL7 were expressed at comparable levels in the two RA-treated cardiomyocyte populations, but at significantly lower levels than those detected in fetal atrial tissue (Figure 14C). Levels of the pacemaker gene TBX3 were comparable in the two RA-treated groups, suggesting that the observed differences in expression of KCNA5, KCNJ3, CACNA1D, and NR2F2 were not due to contaminating pacemaker cells in the atrial population (Figure 13D).

[0136] Considering that CD235a+ mesoderm expresses CYP26A1, which can degrade RA, the difference in expression of atrial genes may be due to differences in the final concentration of active ligand reaching the nuclear receptor. To test this, we varied the concentration of RA used for atrial lineage commitment and analyzed isolated NKX2-5+SIRPa+ cells (day 20) generated from each EB induction condition (Figure 13E). Increasing the concentration of RA from 0.5 mM to 1-2 mM increased the expression level of KCNA5 in cardiomyocytes from VI EBs to levels comparable to cells from AI EBs (Figure 13F). These concentrations of RA were also sufficient to completely suppress the expression of ventricular genes MYL2 and IRX4 in the VI population (Figure 13G). In contrast, the addition of RA at concentrations up to 2 mM did not increase the expression of KCNJ3, CACNA1D, and NR2F2 in VI cardiomyocytes to levels observed in AI cells (Figure 14H). Comparable expression levels of these genes were detected only in cardiomyocytes generated from EBs treated with 4 mM RA, a concentration that resulted in a dramatic reduction in the frequency of NKX2-5+SIRPa+ cells in the day 20 population (Figure 14E). These data further demonstrate that VI and AI mesoderm populations do not have the same differentiation capacity. Furthermore, they highlight the importance of using appropriate early induction strategies for efficient lineage commitment of ventricular and atrial cardiomyocytes. To assess whether the populations are functionally distinct, we tested the electrophysiological characteristics of NKX2-5+SIRPa+CD90- cardiomyocytes derived from VI and AI±RA EBs using patch clamp experiments.

[0137] Table 1 (referring to FIG. 6) Electrophysiological characteristics of cardiomyocytes derived from VI and AI EBs.

[0138] [Table 1]

[0139] APA, action potential amplitude; APD30 / 90, duration of action potential at 30% / 90% of repolarization; CL, cycle length; DMP, diastolic membrane potential; dv / dtmax, maximum action potential rise velocity; t-test: *P<0.05, **P<0.01 for VI-autonomous and #P<0.05, ##P<0.01 for VI+RA. %±SEM of AP types were quantified from n=5 (VI, VI+RA) and n=6 (AI+RA) patch-analyzed cell batches of independent differentiation. Details of the parameters used for classification into AP types are specified in the Methods section.

[0140] Since flow cytometric analysis of MLC2V already demonstrated low efficiency of lineage commitment of ventricular cardiomyocytes from AI EBs in the absence of RA, these cardiomyocytes were not further analyzed in patch clamp experiments. Cardiomyocytes derived from VI EBs (in the absence of RA) exhibited typical ventricular action potentials (APs) with rapid rise rates (>10 V / s) and long AP durations (APD30>50 ms) (Figure 6E and Figure 6F). Importantly, 100% of the analyzed cells exhibited this ventricular phenotype (Figure 6G). Cardiomyocytes committed from VI or AI EBs in the presence of RA exhibited significantly faster beating rates and shorter APD30 compared to cardiomyocytes derived from VI EBs, pointing to an atrial AP phenotype (Figure 6E and Figure 6F). However, APD30 and APD90 of VI+RA EB-derived cardiomyocytes were significantly longer than those found in AI+RA EB-derived cardiomyocytes (APD30, 55±20ms vs. 13.0±4.8ms; APD90, 258±25ms vs. 189±18ms). Classification of the types of APs observed revealed striking differences in the percentage of atrial- and ventricular-like APs recorded in cells from the two groups (Figure 6G). Only 62%±5% of analyzed cells from VI+RA EBs showed an atrial pattern, while the remaining 38%±5% showed a ventricular phenotype (APD30 / 90>0.3). In contrast, the majority of cells in AI+RA EBs (86%±9%) showed an atrial pattern, and only 6%±6% showed ventricular APs. One out of 20 recorded cells from AI+RA EBs had a slow rise rate (<10V / s) and slow beating rate (50 bpm), indicative of immature cardiomyocytes. To further characterize atrial cells generated from the two EB populations, we next measured acetylcholine-activated potassium current density (IKACh), focusing only on cells that exhibited an atrial AP phenotype (rise rate >10V / s, APD30 / 90 <0.3). As expected, ventricular cells derived from control VI EBs (-RA) showed significantly smaller IKACh current density than atrial cells generated from both populations (Figures 6H-6J).Comparison of the two atrial cardiomyocyte populations revealed interesting differences, with those derived from AI+RA EBs exhibiting significantly higher IKACh current densities than those derived from VI+RA EBs (2.8±0.4pA / pF vs. 1.6±0.4pA / pF). Taken together with the above observations, these findings indicate that the efficiency of atrial cell generation and the quality of these cells depend on generating the appropriate mesodermal population.

[0141] Generation of atrial and ventricular cardiomyocytes from other hPSC lines

[0142] To determine whether the approach to optimize atrial and ventricular differentiation based on ALDH activity and CD235a expression is broadly applicable, we next used it to generate these cardiomyocyte populations from HES2 human embryonic stem cells and MSC-iPS1 induced pluripotent stem cell lines. Titration studies identified 5B / 2A and 5B / 6A for HES2 cells as optimal for atrial and ventricular induction, respectively, and 4B / 4A for MSC-iPSC1 cells as optimal for ventricular induction (Figure 7A, Figure 7B, Figure 7E, and Figure 7F; Mendeley http: / / dx.doi.org / 10.17632 / 7z7d5v2c3w.1). Optimization of atrial induction from MSC-iPSC1 cells was more challenging, with all cytokine combinations promoting the development of a substantial CD235a+ population. One interpretation of these patterns is that MSC-iPS1 cells have high levels of endogenous Nodal / Activin A signaling, resulting in some generation of CD235a+ cells under all conditions. To test this, we added the Nodal / Activin A / Transforming Growth Factor Beta (TGF-beta) inhibitor SB-431542 (SB) to 4B / 1A-induced cells on days 3-5. Addition of SB led to a reduction in CD235a+ cells and an increase in the size of the ALDH+ population without affecting the CTNT+MLC2V-cardiac differentiation capacity of day 4 mesoderm (Figure 7E, Figure 7F, and Figure 14A), supporting the interpretation that MSC-iPS1 cells have higher levels of endogenous Nodal / Activin A signaling than the other lines.

[0143] EBs optimized for CD235a+ mesoderm development from both lines generated day 20 populations containing a high percentage of MLC2V+CTNT+ cardiomyocytes expressing IRX4 (Figures 7B, 7C, 7F, and 7G). Neither CD235a+ mesoderm population responded to ROH. As expected, both responded to RA and generated populations of cardiomyocytes that exhibited reduced MLC2V content, downregulation of MYL2 and IRX4 expression, and upregulation of KCNJ3 and NR2F2 compared to untreated controls (Figures 7B-7D, 7F-7H, and 14B-14G). EBs optimized for ALDH+ mesoderm development responded to both ROH and RA and generated cardiomyocyte populations that displayed an expression profile pointing to an atrial lineage (Figures 7B-7D, 7F-7H, and 14B-14G). Taken together, these findings demonstrate that ALDH+ and CD235a+ mesodermal populations generated from different hPSC lines display atrial and ventricular differentiation capabilities, respectively, similar to populations generated from the HES3-NKX2-5eGFP / w line. Aiming to map the emergence and segregation of atrial and ventricular cardiomyocyte lineages, we used an hPSC differentiation system to model the earliest stages of human cardiac development. Findings from this study support a scheme of human cardiac development in which atrial and ventricular cardiomyocytes originate from distinct mesodermal populations that are lineage-committed by different levels of activin A and BMP4 signaling and can be identified based on ALDH activity (RALDH2) or CD235a / CYP26A1 expression, respectively (Figure 7I). Atrial cardiac development is driven by RALDH2 + In a subpopulation of mesoderm, CD235a is induced via autocrine RA signaling, whereas CD235a is induced via expression of CYP26A1. + We propose that inhibition of the pathway in the mesoderm is required for ventricular cardiomyocyte development. + and CD235a +Although the population can give rise to both types of cardiomyocytes, efficient generation of atrial and ventricular cells depends on proper mesoderm induction. Together, these new insights provide a framework to access the earliest stages of human heart development and a platform for designing optimal protocols for the efficient generation of specific cardiomyocyte subtypes.

[0144] Our observation that atrial lineage commitment is mediated by RA signaling during the mesodermal stage of development is consistent with previous reports on atrial differentiation from hPSCs (Devalla et al., 2015; Zhang et al., 2011), as well as the time-constrained effects of RA on heart development described in early embryos (Moss et al., 1998; Xavier-Neto et al., 2000). In the embryo, this stage is associated with the appearance of a population of RA-responsive and RALDH2-expressing cells in the lateral plate mesoderm that are thought to contribute to the posterior region of the heart tube and ultimately give rise to atrial cardiomyocytes (Hochgreb et al., 2003; Moss et al., 1998). The highly overlapping patterns of RA-responsiveness and RALDH2 expression suggest that this mesoderm can both synthesize and respond to RA. The idea that a subpopulation of cardiac mesoderm can synthesize RA in vivo is supported by the migratory Mesp1 markers that contribute to atrial development. + This is supported by the work of Lescroart et al. (2014), who showed that mesoderm (E7.25) expresses significantly higher levels of ALDH1A2 (RALDH2) than early migratory ventricular progenitors (E6.25-6.75). The findings from our cell sorting experiments clearly demonstrate that 3B / 2A-induced mesoderm with atrial differentiation capacity expresses RALDH2 and can respond to ROH, providing compelling evidence that human atrial lineage commitment is mediated through autocrine RA signaling.

[0145] CD235a + CYP26A1 + ALDH -The finding that mesoderm efficiently generates ventricular cardiomyocytes, but not atrial cells, in response to ROH provides strong evidence that these cardiomyocyte subtypes are derived from distinct mesodermal populations. + and ALDH + Differential expression of CYP26A1 and RALDH2 in the mesoderm indicates that these hPSC-derived progenitors have established a balance between RA synthesis and degradation that resembles the boundary of RA signaling seen along the anterior-posterior axis of the cardiovascular progenitor field in the developing embryo (Cunningham and Duester, 2015; Rydeen and Waxman, 2014). Currently, it is not known whether CD235a mesoderm generates left or right ventricular cardiomyocytes or a mixture of both. Until we can achieve a better elucidation of these populations in vitro, it will be difficult to incorporate our findings into first and second heart field models that propose that different progenitors contribute to the left and right ventricular outflow tracts (Buckingham et al., 2005; Meilhac et al., 2004; Spaeter et al., 2013). However, our findings are in line with those of Bardot et al. (2017) who used a lineage tracing strategy to show that FOXA2 expression in mice marks progenitor cells that give rise to left and right ventricular, but not atrial, cardiomyocytes.

[0146] The ability to quantitatively monitor the development of ventricular and atrial progenitors through CD235a expression and ALDH activity allowed us to study the pathways regulating the lineage commitment of these two populations and to demonstrate that gradients of BMP4 and Activin A signaling play a pivotal role in these early decisions. Our analysis of different hPSC lines revealed that lineage commitment of the ventricular lineage depends on a higher ratio of Activin A to BMP4 signaling than is required for the generation of the atrial lineage. These differences may reflect the different signaling environments to which these progenitors are exposed in the early embryo. Supporting evidence for this is provided by the study of Lescroart et al. (2014), who showed that transcripts of Nodal as well as its downstream target genes PITX2, LEFT1, FGF8, GSC, and MIXI (Lee et al., 2011) are enriched in early migratory left ventricular progenitors compared to later-developing atrial progenitors.

[0147] The observation that optimal ventricular and atrial development depends on efficient lineage commitment of the appropriate mesoderm highlights the importance of understanding the early stages of development in hPSC differentiation cultures. Our findings show that both the efficiency of lineage development and, in the case of atrial cardiomyocytes, the quality of cells generated are affected by the initial induction step. Precise control of lineage development in differentiation cultures has important implications for translating the differentiation capacity of hPSCs into therapeutic applications for cardiovascular disease. For example, highly enriched ventricular cardiomyocytes, devoid of contaminating pacemaker cells and atrial cells, would be an ideal candidate population for developing cell-based therapies aimed at rehypertrophy of the ventricular wall muscle in patients suffering from myocardial infarction. Removal of non-ventricular cells could reduce arrhythmias observed in animal models following transplantation of a mixed population of hPSC-derived cardiomyocytes (Chong et al., 2014; Shiba et al., 2016). Access to enriched populations of cardiomyocyte subtypes is also important for modeling diseases that affect specific regions of the heart, such as atrial fibrillation, hypertrophic cardiomyopathy, and other chamber-specific congenital heart defects. The ability to generate distinct cardiac populations will not only provide suitable target cells for such studies, but also allow for the analysis of potential off-target effects of therapeutic strategies on other cardiomyocyte subtypes. These comprehensive analyses will provide insights into human cardiovascular disease that are not possible with the use of poorly characterized mixed populations.

[0148] Learn how

[0149] Directed differentiation of human ESC / iPSC lines

[0150] For cardiac differentiation, we used a modified version of our embryoid body (EB)-based protocol (Kattman et al., 2011). 80%–90% confluent hPSC populations were dissociated into single cells (TrypLE, ThermoFisher) and reaggregated to form EBs for 18 h on an orbital shaker in StemPro-34 medium (ThermoFisher) containing penicillin / streptomycin (1%, ThermoFisher), L-glutamine (2 mM, ThermoFisher), transferrin (150 μg / ml, ROCHE), ascorbic acid (50 μg / ml, Sigma), and monothioglycerol (50 μg / ml, Sigma), ROCK inhibitor Y-27632 (10 μM, TOCRIS), and rhBMP4 (1 ng / ml, R&D). On day 1, EBs were transferred to mesoderm induction medium consisting of StemPro-34 with the indicated concentrations of the above supplements (-ROCK inhibitor Y-27632) as well as rhBMP4, rhActivin A (R&D) and rhbFGF (5ng / ml, R&D). On day 3, EBs were harvested, washed in IMDM and transferred to cardiac mesoderm lineage commitment medium consisting of StemPro-34, WNT inhibitor IWP2 (1μM, TOCRIS) and rhVEGF (10ng / mL, R&D). On day 5, EBs were transferred to StemPro-34 with rhVEGF (5ng / ml) for an additional 7 days, followed by StemPro-34 medium without additional cytokines for an additional 8 days. On day 20, cardiomyocytes derived from HES3-NKX2-5gfp / w were analyzed and isolated based on expression of NKX2-5:GFP and SIRPa and lack of CD90. Cardiomyocytes generated from non-transgenic hPSC lines were analyzed and isolated as a SIRPa+CD90- population. Media was changed every 3 days. Cultures were incubated in a hypoxic environment (5% CO2, 5% O2, 90% N2) for the first 12 days, followed by a normoxic environment (5% CO2) for the next 8 days (total 20 days). EBs were cultured in ultra-low attachment 6-well dishes (Corning) throughout differentiation to maintain suspension culture.

[0151] Optimization of atrial and ventricular lead conditions

[0152] To determine optimal atrial induction conditions, the selection of Activin A and BMP4 concentrations was based on the identification of the mesoderm population with the highest percentage of ALDH+CD235a- cells on day 4 that showed the highest ability to generate CTNT+MLC2V- cardiomyocytes on day 20. After optimization, either ATRA (0.5 μM, Sigma) or retinol (2 μM, Sigma) was included in the cardiac mesoderm lineage commitment medium on days 3–5 for the generation of atrial cardiomyocytes.

[0153] To determine optimal ventricular induction conditions, the selection of Activin A and BMP4 concentrations was based on the identification of a mesoderm population that contained a high percentage of CD235a+ cells, no ALDH+ cells, and generated a high percentage of CTNT+MLC2V+ at day 20.

[0154] Flow cytometry and cell sorting

[0155] Day 2–6 EBs were dissociated with TrypLE for 2–4 min at room temperature (RT). Day 20 EBs were dissociated by overnight incubation at RT in collagenase type 2 (0.5 mg / ml, Worthington) in Hanks buffer followed by TrypLE treatment as above. The following antibodies were used for staining: anti-PDG-FRa-PE (R&D Systems, 3:50), anti-CD235a-APC (BD PharMingen, 1:100), anti-SIRPa-PeCy7 (Biolegend, 1:1000), anti-CD90-APC (BD PharMingen, 1:1000), anti-CTNT cardiac isoform (ThermoFisher Scientific, 1:2000), or anti-myosin light chain 2 (Abeam, 1:1000). For unconjugated primary antibodies, the following secondary antibodies were used for detection: goat anti-mouse IgG-APC (BD Pharmigen, 1:250), or donkey anti-rabbit IgG-PE (Jackson ImmunoResearch, 1:250). Detailed antibody information is listed in Table 2.

[0156] Table 2 Experimental resources

[0157] [Table 2-1] [Table 2-2]

[0158] [Table 3-1] [Table 3-2]

[0159] For analysis of cell surface markers, cells were stained for 30 min at 4°C in FACS buffer consisting of PBS with 5% fetal calf serum (FCS) (Wisent) and 0.02% sodium azide. For intracellular staining, cells were fixed with 4% PFA in PBS for 15 min at 4°C, followed by permeabilization with 90% methanol for 20 min at 4°C. Cells were washed with PBS containing 0.5% BSA (Sigma) and stained with unconjugated primary antibodies in FACS buffer overnight at 4°C. Stained cells were washed with PBS containing 0.5% BSA and stained with secondary antibodies in FACS buffer for 1 h at 4°C.

[0160] Stained cells were analyzed using an LSR II Flow cytometer (BD). For cell sorting, stained cells were kept in IMDM containing 0.5% FCS and sorted at the Sickids / UHN flow cytometry facility using Influx (BD), FACSAriall (BD), MoFlo-XDP (BD) and FACSAria Fusion (BD). Data were analyzed using FlowJo software (Tree Star).

[0161] Aldefluor assay

[0162] The aldefluor™ assay (STEMCELL Technologies) was performed according to the instructions provided by the manufacturer. Briefly, day 2-6 EBs were dissociated as described above. Cells were stained at a concentration of 2×106 cells / ml in aldefluor assay buffer containing 0.1% BSA and BAAA substrate (0.12 mg / ml) for 60 min at 37°C. The aldehyde dehydrogenase inhibitor DEAB (0.75 nM) was added to negative control samples. Cells were washed with cold medium consisting of IMDM with 5% FCS and 10% aldefluor assay buffer. Cells were then stained with antibodies to cell surface markers at the concentrations indicated above in chilled wash medium for an additional 20 min at 4°C. Stained cells were analyzed as described above. Cells were kept in chilled wash medium during analysis. For cell sorting, FCS was replaced with KnockOut™ serum replacement (ThermoFisher) to avoid any influence of serum-containing cytokines on cell differentiation. Cells were maintained in StemPro-34 containing 10% aldefluor assay buffer throughout the sorting procedure. Sorted cells were harvested and reaggregated in StemPro-34 containing ROCK inhibitor (10 μM), IWP2 (0.5 μM) and rhVEGF (5 ng / ml).

[0163] immunohistochemistry

[0164] Day 20 EBs were dissociated as described above and cells were plated onto 12 mm glass coverslips (VWR) pre-coated with Matrigel (25% v / v, BD). Cells were cultured for 3–5 days to allow for the formation of a monolayer of adherent cells.

[0165] Cells were fixed with 4% PFA in PBS for 10 min at room temperature and permeabilized with PBS containing 0.3% TritonX, 200 mM glycine (Sigma) for 20 min at RT. Cells were blocked with PBS containing 10% FCS, 0.1% TritonX, and 2% BSA. The following antibodies were used for staining: mouse anti-CTNT cardiac isoform (ThermoFisher Scientific, 1:200), rabbit anti-human / rodent myosin light chain 2 (Abcam, 1:200), mouse anti-human COUPTF-II (R&D, 1:1000), or rabbit anti-human CTNT (Genway Biotech Inc., 1:1000). To detect unconjugated primary antibodies, the following secondary antibodies were used: donkey anti-mouse IgG-A647 (ThermoFisher, 1:1000), or donkey anti-rabbit IgG-A555 (ThermoFisher, 1:1000). Detailed antibody information is listed in the Key Resources Table. Cells were stained with primary antibodies in staining buffer consisting of PBS with 0.1% TritonX and 0.1% BSA overnight at 4°C. Stained cells were washed with staining buffer for 15 min at RT on an orbital shaker. Cells were then stained with secondary antibodies in staining buffer for 1 h at RT, followed by washing steps as described above. Samples were mounted using SlowFade Gold Antifade reagent with DAPI (ThermoFisher). Stained cells were analyzed using an Olympus FluoView 1000 Laser Scanning Confocal Microscope. FV10-ASW software was used for image acquisition.

[0166] Quantitative real-time PCR

[0167] Total RNA was isolated from hPSC-derived populations using the RNAqueous-micro Kit (Ambion) with RNase-free DNase treatment. RNA from dissected ventricular and atrial tissues of human fetal hearts was isolated using the TRIzol method (ThermoFisher) and treated with DNase (Ambion). 100ng–1mg of isolated RNA was reverse transcribed into cDNA using oligo(dT) primers and random hexamers and Superscript III reverse transcriptase (ThermoFisher). QRT-PCR was performed on an EP Real-Plex MasterCycler (Eppendorf) using the QuantiFast SYBR GREEN PCR kit (QIAGEN). All experiments were prepared in duplicate and included 10-fold serial dilutions of sonicated human genomic DNA standards ranging from 25ng / ml to 2.5pg / ml to assess the efficiency of the PCR reaction and the copy number of each gene relative to the housekeeping gene TBP. Heat maps of gene expression data were generated using MultiExperiment Viewer (MeV) open source software.

[0168] Patch clamp

[0169] For electrophysiological characterization using patch clamp, EBs were dissociated and NKX2-5+SIRPa+CD90- cardiomyocytes were isolated by FACS as described above. Isolated cells were suspended at 1.25–5×105 cells / ml in StemPro-34 medium supplemented with ROCK inhibitor (10 mM) and filtered through a 70 mm filter. A 40 ul drop of this cell suspension was applied onto a glass coverslip (3×5 mm) pre-coated with Matrigel (10% v / v) in a 30 mm dish. Cells were incubated for 16–18 h in a volume of 40 mL to promote cell attachment. The dish was then filled with 2 ml of StemPro-34 medium. Medium was changed every 4 days. Cultures were used for patch clamp recordings 7–14 days after plating. APs and membrane currents were measured using standard patch clamp techniques in current and voltage clamp modes, respectively (Axopatch 200B, Molecular Devices). Voltages and currents were recorded (DigiData, Molecular Devices) at a sampling rate of 5 KHz and analyzed using pCLAMP software (Molecular Devices). Borosilicate glass microelectrodes with a tip resistance of 2–5 MU when filled with pipette solution were used. Series resistance was corrected at rv70%. APs and membrane currents were recorded at RT using the whole-cell ruptured patch technique with the following bath solution (in mM): NaCl 140, KCl 5.4, CaCl2 1.2, MgCl2 1, glucose 10, and HEPES 10 (pH 7.4, adjusted with NaOH). Pipette solution consisted of the following (in mM): potassium aspartate 120, KCl 20, NaCl 5, MgATP 5, and HEPES 10 (pH 7.2, adjusted with KOH).

[0170] In resting cardiomyocytes, APs were evoked by 1-3 ms long depolarizing current pulses of 5-15 pA at a frequency of 1 Hz. Autonomic and stimulated APs were classified based on the following parameters: pacemaker-like: dv / dtmax<10 V / s, atrial-like: dv / dtmax R 10 V / s and APD30 / 90 R 0.3, ventricular-like: dv / dtmax R 10 V / s and APD30 / 90 R 0.3. Acetylcholine-activated potassium currents (IKACh) were characterized as CCh-sensitive currents (activated by CCh). Currents were measured before and after the addition of carbachol (CCH, 10 mM) in response to a 350 ms voltage ramp protocol spanning 20 mV to -120 mV from a holding potential of -40 mV (see inset of voltage protocol in each original current trace). IKACh was quantified by subtracting the current recorded without CCh from the current recorded in the presence of CCh.

[0171] Quantification and statistical analysis

[0172] All data are expressed as mean ± standard error of the mean (SEM). The indicated sample sizes (n) represent independent cell culture replicates and biological replicates including individual tissue samples. For single cell data (quantification of beating rate and patch clamp data), sample sizes (n) represent the number of cells analyzed from three independent experiments in R. No statistical methods were used to predetermine sample size. Due to the nature of the experiments, no randomization was performed and investigators were not blinded. Statistical significance was determined by using Student's t-test (unpaired, two-tailed) in GraphPad Prism 6 software. Results were considered significant at p<0.05 (* / #) and highly significant at p<0.01 (** / ##). All statistical parameters are reported in each figure and in the figure legends.

[0173] Although preferred embodiments of the invention have been described herein, it will be understood by those skilled in the art that variations can be made thereto without departing from the spirit of the invention or the scope of the appended claims. All documents disclosed herein, including those in the reference list below, are incorporated by reference.

Claims

[Claim 1] The invention as depicted in the drawings.